 
 Title:  Phase 1 Feasibility Trial of Inhaled Tobramycin in Preterm Infants with Bronchopulmonary 
Dysplasia  
 
ClinicalTrials.gov  ID: [STUDY_ID_REMOVED]   
 
Sponsor : Erik Allen Jense n, MD  
 
Document Da te:  June 20, 2023  
 
  
   
  
   ii 
 
Title:  Phase 1 Feasibility Trial of Inhaled Tobramycin in Preterm 
Infants with Bronchopulmonary Dysplasia  
Short Title Phase 1 Trial of Inhaled Tobramycin in BPD  
Drug or Device 
Name(s):  Tobramycin solution (300mg/5mL) for inhalation USP  
FDA IND 145836 
Funding agency  National Heart Lung and Blood Institute ( R34HL155690)  
Regulatory Sponsor:  Erik Jensen, MD , MSCE  
eIRB Number  IRB 19 -016800  
Protocol Date:  July 22, 2019  
Amendment 1 Date:  October 18 , 2019  Amendment 5 Date:  November 12, 2021  
Amendment 2 Date:   December 23, 2019  Amendment 6 Date: January 25, 2022  
Amendment 3 Date: April 3, 2020  Amendment 7 Date: March 2, 2022  
Amendment 4 Date: June 2, 2020  Amendment 8 Date: April 6, 2022  
Amendment 9 Date: June 20, 2023  
 
Study Principal Investigator  
[INVESTIGATOR_195920], MD MSCE  
Children’s Hospi[INVESTIGATOR_195921]  
[ADDRESS_232790] –  Suite [ZIP_CODE]  
 Philadelphia, PA, [ZIP_CODE]  
Phone [PHONE_4253]  
email: [EMAIL_3878] 
 
 
    
   
   iii 
TABLE OF CONTENTS  
Table of Contents  .................................................................................................................. iii 
Abbreviations and Definitions of Terms ............................................................................. vi 
Abstract  ................................................................................................................................ vii 
Protocol Synopsis  ................................................................................................................... x 
Table 1: Schedule of Study Procedures  ............................................................................. xv 
Figure 1: Study enrollment and phases flow diagram…………………………………..xii  
Figure 2: 3+3 dose escalation design schematic  .............................................................. xvii 
1 BACKGROUND INFORMATION AND RATIONALE  ....................................................................... 1 
1.1 INTRODUCTION  ..................................................................................................................................... 1 
1.2 BURDEN OF BRONCHOPULMONARY DYSPLASIA (BPD)  ......................................................................... [ADDRESS_232791]  ................................................................... 2 
1.6 FINDINGS FROM CLINICAL STUDIES  ..................................................................................................... 2 
1.6.1  Human pharmacokinetics  ................................................................................................................ 2 
1.6.2  Potential toxicity with inhaled tobramycin  ...................................................................................... 6 
1.7 RATIONALE FOR DRUG DOSAGES AND DURATION UNDER INVESTIGATION  ............................................ 8 
1.8 COMPLIANCE STATEMENT  .................................................................................................................... 9 
2 STUDY OBJECTIVES  .............................................................................................................................. 9 
2.1 PRIMARY OBJECTIVE  ............................................................................................................................ 9 
2.2 SECONDARY OBJECTIVES  ..................................................................................................................... 9 
3 INVESTIGATIONAL PLAN  .................................................................................................................. 10 
3.1 GENERAL SCHEMA OF STUDY DESIGN  ............................................................................................... 10 
3.1.1  Screening Phase  ............................................................................................................................ 10 
3.1.2  Phase 1 Trial  .................................................................................................................................  10 
3.1.3  Observational Cohort  .................................................................................................................... 11 
3.1.4  Follow -up Phase  ........................................................................................................................... 11 
3.2 ALLOCATION TO TREATMENT AND MASKING  .................................................................................... 12 
3.3 STUDY DURATION , ENROLLMENT , AND NUMBER OF SITES ................................................................ 12 
3.3.1  Duration of Study Participation .................................................................................................... 12 
3.3.2  Total Number of Study Sites/Total Number of Subjects Projected ................................................ [ADDRESS_232792] COMPLETION /WITHDRAWAL  ............................................................................................... [ADDRESS_232793] Review  ................................................................................................................. 19 
5.1.2  Clinical Data Warehouse………………………………………………………………………………….[ADDRESS_232794] Stoppi[INVESTIGATOR_1869]  .................................................................................................  25 
5.2.5  Study Stoppi[INVESTIGATOR_1869]  ..................................................................................................................... 25 
5.3 EFFICACY EVALUATIONS  ................................................................................................................... 26 
5.4 PHARMACOKINETIC EVALUATION  ...................................................................................................... 28 
6 STATISTICAL CONSIDERATIONS  .................................................................................................... 28 
6.1 PRIMARY ENDPOINT  ........................................................................................................................... 28 
6.2 SECONDARY ENDPOINTS  .................................................................................................................... 28 
6.3 STATISTICAL METHODS ...................................................................................................................... 29 
6.3.1  Baseline Data  ................................................................................................................................ 29 
6.3.2  Safety Analysis  .............................................................................................................................. 29 
6.3.3  Efficacy Analysis  ........................................................................................................................... 29 
6.3.4  Pharmacokinetic analysis  ............................................................................................................. 31 
6.4 SAMPLE SIZE AND POWER  .................................................................................................................. 32 
6.5 INTERIM ANALYSIS  ............................................................................................................................ 32 
7 STUDY MEDICATION (TOBRAMYCIN INHALATIONAL SOLUTION, USP)  ........................... 32 
7.1 DESCRIPTION  ...................................................................................................................................... 32 
7.1.1  Packaging  ...................................................................................................................................... 33 
7.1.2  Labeling  ........................................................................................................................................ 33 
7.1.3  Dosing ........................................................................................................................................... 33 
7.1.4  Drug delivery via vibrating mesh nebulizer  .................................................................................. 33 
7.1.5  Treatment Compliance and Adherence  ......................................................................................... 34 
7.1.6  Drug Accountability  ...................................................................................................................... 34 
8 SAFETY MANAGEMENT  ..................................................................................................................... 34 
8.1 CLINICAL ADVERSE EVENTS  .............................................................................................................. 34 
8.2 ADVERSE EVENT REPORTING  ............................................................................................................. 35 
8.3 DEFINITION OF AN ADVERSE EVENT  .................................................................................................. 35 
8.4 DEFINITION OF A SERIOUS ADVERSE EVENT (SAE)  ........................................................................... 36 
8.4.1  Relationship/Severity of SAE to Study Drug or Other Intervention  .............................................. 36 
8.5 IRB/IEC  NOTIFICATION OF SAE S AND OTHER UNANTICIPATED PROBLEMS  ...................................... 36 
8.5.1  Follow -up report  ........................................................................................................................... 36 
8.6 INVESTIGATOR REPORTING OF A SERIOUS ADVERSE EVENT TO SPONSOR  .......................................... 37 
8.7 SPONSOR REPORTING OF SERIOUS ADVERSE EVENTS TO FDA  .......................................................... 37 
8.8 MEDICAL EMERGENCIES  .................................................................................................................... 37 
9 STUDY ADMINISTRATION ................................................................................................................. 37 
9.1 TREATMENT ASSIGNMENT METHODS .................................................................................................  37 
9.2 DATA COLLECTION AND MANAGEMENT  ............................................................................................ 37 
9.3 CONFIDENTIALITY  .............................................................................................................................. 37 
9.4 REGULATORY AND ETHICAL CONSIDERATIONS .................................................................................. 38 
9.4.1  Data and Safety Monitoring Plan  .................................................................................................  38 
9.4.2  Risk Assessment  ............................................................................................................................. 41 
    
   
   v 
9.4.3  Potential Benefits of Tr ial Participation  ....................................................................................... 42 
9.4.4  Risk-Benefit Assessment  ................................................................................................................ 42 
9.5 RECRUITMENT STRATEGY  .................................................................................................................. 42 
9.6 INFORMED CONSENT /ASSENT AND HIPAA  AUTHORIZATION  ............................................................ 43 
9.6.1  Waiver of Assent  ............................................................................................................................ 44 
9.7 PAYMENT TO SUBJECTS /FAMILIES  ..................................................................................................... 44 
10 PUBLICATION  ............................................................................................................................... 44 
11 REFERENCES  ................................................................................................................................ 45 
Appendix  ............................................................................................................................... 52 
 
    
   
   vi 
ABBREVIATIONS AND DEFINITIONS OF TERMS  
a-TEOAE   Automated transient evoked otoacoustic emissions  
AAP  American Academy of Pediatrics  
ABR  Auditory brainstem response  
AE  Adverse event  
AKI  Acute kidney injury  
BAEP   Brainstem auditory evoked potential  
BAL  Bronchoalveolar lavage  
BPD  Bronch opulmonary dysplasia  
CCP   Center for Clinical Pharmacology  
CF  Cystic fibrosis  
CFU  Colony forming units  
CHOP   Children’s Hospi[INVESTIGATOR_195922] 2  Fraction of inspi[INVESTIGATOR_195923] -negative rod  
HPLC -MS/MS   High-performance liquid chromatography tandem mass spectrometry  
IDS  Investigational drug services  
IND  Investigational new drug  
IV  Intravenous  
JCIH   Joint Committee on Infant Hearing  
KDIGO   Kidney disease improving global outcomes  
MAP   Mean airway pressure  
MIC  Minimum inhibitory concentration  
MTD   Maximum tolerated dose  
NeoCLD   Newborn and Infant chronic lung disease (program at CHOP)  
N/IICU   Newborn and infant intensive care unit  
OAE   Otoacoustic emissions  
OI  Oxygenation index  
PI  [INVESTIGATOR_195924]/AST   Aspartate aminotransferase  
SGPT/ALT   Alanine aminotransferase  
SpO [ADDRESS_232795]  
Context :  
Bronchopulmonary dysplasia (BPD) is among the most common and consequential chronic 
complications associated with preterm birth. Among infants with BPD who continue to 
require invasive mechanical ventilation near term corrected gestation, airway colonizati on 
with a pathogenic Gram -negative rod (GNR) bacteria is an independent risk factor for 
prolonged need for supplemental oxygen and home oxygen therapy. Inhaled tobramycin is an effective therapy for treating airway infections secondary to GNR bacteria and has 
shown clinical benefit when used in several pediatric and adult chronic respi[INVESTIGATOR_195925] . The safety and efficacy  of inhaled tobramycin in preterm infants with BPD  and 
GNR bacteria present in the airways is unknown.  
 
Objectives : 
The objective of this open- label , phase 1, inter-patient  dose escalation feasibility trial is to 
identify  a safe, well tolerated dose of inhaled tobramycin for use in very preterm infants with 
BPD receiving invasive mechanical ventilation who have evidence of a pathogenic GNR 
detected by [CONTACT_196088][INVESTIGATOR_195926].  
 
Study Design:  
Prospective  open- label, phase 1, inter -patient  3+3 dose escalation feasibility trial. An 
untreated, observational cohort of eligible infants will also be enrolled.  
 
Setting/Participants:  
This trial will take place in the newborn and infant intensive care unit (N/IICU) at the 
Children’s Hospi[INVESTIGATOR_6684]. This will be the only site. Up to 103 infants will be 
enrolled in this  study  to produce up to 24 infants with evaluable trial data and up to 28 
participants in the observational cohort. The trial will use the following  inclusion/exclusion 
criteria: 
 
Inclusion Criteria : 
1. Male or female infants born <32 weeks’ gestation 
2. Diagnosed with BPD (use of supplemental oxygen or respi[INVESTIGATOR_158728] 36 weeks postmenstrual age
1) 
3. Postmenstrual age ≥36 weeks at study enrollment  
4. Treatment with invasive mechanical ventilation at enrollment without planned tracheal extubation within 7 days  after enrollment  
5. Tracheal aspi[INVESTIGATOR_195927] a pathogenic GNR bacteria ( see list of eligible 
organisms in section 3.4.3) within 7 days of beginning the study phase – this testing 
will be performed during the screening phase and must be met to participate in the 
phase 1 trial or observational cohort   
6. Parental/guardian permission (informed consent).  
Exclusion Criteria : 
1. Serum creatinine >0.4mg/dL within [ADDRESS_232796] s renal function 
3. Congenital or acquired hepatobiliary disease that adversely affects liver function  
4. Treatment with a systemic antibiotic  within 7 days  prior to enrollment  
 
1 Postmenstrual age (PMA) is calculated as the gestational age at birth plus the chronological age  
 
   
   
   viii 
5. Treatment with a nephrotoxic medication (see list in appendix A), excluding 
diuretics , within 48 hours prior to  enrollment  
6. Treatment with a continuous infusion of  a neuromuscular blocker ( see list in 
Appendix B) within 48 hours prior to  enrollment  
7. Known intolerance to aminoglycoside antibiotics  
8. Current treatment with high frequency or other oscillating mechanical ventilation 
9. Presence of a cancer diagnosis  
10. Maternal family history of early onset hearing loss defined as the need for an 
assistive hearing device prescribed before 30 years of age  
11. Persistent endotracheal tube leak >20%.  
12. Any prior use of an investigational drug as part of an FDA  approved IND protocol .  
13. A subject who, in the judgement  of the Investigator, is not an appropriate candidate 
for this research study . 
Study Interventions and Measures :  
The study will investigate tobramycin solution for inhalation (300mg/5mL). Up to 4 different 
dosages  will be investigated : 78mg , 150mg, 216mg, and 300mg , all administered every 12 
hours  for up to 14 days.  
 
The primary study outcome is a composite safety endpoint defined by [CONTACT_196089] 14- day trial: 
1) Trough serum tobramycin level (measured 11 hours after the administered dose) 
≥1mcg/mL  
2) Increase in serum creatinine level by ≥0.3mg/dL above pre-trial baseline 
3) Increase in serum creatinine level >1.5 -fold above pre -trial baseline 
4) Urine output <0.5mL/kg/hr for 12 consecutive hours  
5) Any serious adverse event  possibly attributable to the study d rug 
 
Occurrence of the primary outcome in ≥ 2 infants at a single dosage level will define the 
“maximum tolerated dose” and result in cessation of the trial.  
 
Additional exploratory secondary safety endpoints  are: 
1) New onset or worsened coughing associated with a change in respi[INVESTIGATOR_82219] 
(SpO 2 <80% for >10 seconds; need for increase in FiO 2 by >20%)  
2) Obstruction of the endotracheal tube requiring tube replacement  
3) Unplanned tracheal extubation 
4) Desaturation (SpO 2 <80% for >10 seconds) during administration of inhaled 
tobramycin  
5) Rates of pre -discharge failed audiology examinations  
6) Rates of new intra -patient microbial resistance  to tobramycin  
 
The exploratory secondary efficacy endpoints  are: 
 
1) Tracheal aspi[INVESTIGATOR_195928] 
2) Change in tracheal aspi[INVESTIGATOR_195929] (CFU) counts  
measured by [CONTACT_120154], quantitative  culture 
3) Change in the following measures of administered respi[INVESTIGATOR_1413] : fraction of 
inspi[INVESTIGATOR_1401] ( FiO 2), ventilator mean airway pressure (MAP), and respi[INVESTIGATOR_195930]  (MAP x FiO 2) 
    
   
   ix 
4) Change in the following measures of hypoxemia (SpO 2<80%): Intermittent 
hypoxemia ( events lasting 10s -3min), prolong hypoxemia ( events lasting >1min), 
and daily proportion of time in hypoxemia  
5) Change in tracheal aspi[INVESTIGATOR_195931] , neutrophil  to total WBC ratio , and 
patterns in the airway microbiome  
6) Change in dynamic lung compliance, airway resistance, peak expi[INVESTIGATOR_10229], and 
carbon dioxide (CO 2) elimination  
  
    
   
   x 
PROTOCOL SYNOPSIS  
Study Title Phase 1 Feasibility Trial of Inhaled Tobramycin in Infants with 
Bronchopulmonary Dysplasia  
Funder  Children’s Hospi[INVESTIGATOR_195932] I  
Study Rationale  Bronchopulmonary dysplasia (BPD) is among the most common 
and consequential chronic complications of preterm birth. 
Colonization or infection of the airway by a pathogenic Gram -
negative rod (GNR) bacteria in preterm infants with BPD receiving 
invasive mechanical ventilation is an independent risk factor for 
prolonged use of  supplemental oxygen and home oxygen therapy. 
Respi[INVESTIGATOR_195933] (the most 
common GNR detected in airways of infants with BPD) is a known risk factor for poor pulmonary function and adverse clinical 
outcomes in several  chronic respi[INVESTIGATOR_14437].  
 
Tobramycin  is an aminoglycoside antibiotic  that has been shown to 
eradicate bacterial airway colonization with P. aeruginosa and other 
pathogenic GNR bacteria in older children and adults  when 
delivered to the lungs via nebulization. T he safety and efficacy of 
inhaled tobramycin in preterm infants with BPD is unknown and 
there are no robust data that inform the optimal dos ing strategy  for 
use in this population.  
Study Objective(s)  Primary   
• To determine the maximum, safely tolerated dose of tobramycin solution for inhalation (selected between 78 mg, 150mg, 216mg, 
and 300mg administered every 12 hours ) in very preterm infants 
with BPD who are actively receiving invasive mechanical 
ventilation and have evidence of a pathogenic GNR bacteria 
(listed in section 3.4.3 ) detected by [CONTACT_196088][INVESTIGATOR_195926].   
Secondary 
• To evaluate the association between the dose of inhaled 
tobramycin, plasma  tobramycin pharmacokinetics,  and peak  
tracheal aspi[INVESTIGATOR_195934] . 
• To compare the change (pre vs. post study ) in tracheal aspi[INVESTIGATOR_195935] (CFU) counts measured 
by [CONTACT_196090],  (1) between participants in the phase 
1 trial and untreated infants in the observational cohort, and (2) between trial participants  stratified by [CONTACT_196091].  
• To compare the change in measures of adminis tered respi[INVESTIGATOR_81407] (FiO 2, ventilator mean airway pressure, and respi[INVESTIGATOR_195930]) during the 14- day study period, (1) between 
participants in the observational cohort and phase  1 trial, and (2)  
between trial participants stratified by [CONTACT_196091].  
    
   
   xi 
• To evaluate changes (pre vs. post treatment) in airway cytokine 
levels , neutrophil /WBC ratio , and patterns in the airway 
microbiome.  
• To compare changes in the following measures of hypoxemia 
(SpO 2<80%): Intermit tent hypoxemia ( events lasting 10s -3min), 
prolong hypoxemia ( events lasting >1min), and daily proportion 
of time in hypoxemia during the 14- day study period, (1) 
between participants in the observational cohort and phase 1 
trial, and (2)  between trial part icipants stratified by [CONTACT_196092].  
 
• To evaluate longitudinal change in dynamic lung compliance, 
airway resistance, peak expi[INVESTIGATOR_10229], and CO 2 elimination  
during the 14- day study period, (1) between participants in the 
observational cohort and phase 1  trial, and (2)  between trial 
participants stratified by [CONTACT_196093].  
Study Drug  Tobramycin solution (300mg/5mL) for inhalation USP  
Study Design  Open-label , inter-patient 3+[ADDRESS_232797] Population  
key criteria for Inclusion and Exclusion:  Inclusion Criteria  
1. Male or female infants born <32 weeks’ gestation 
2. Diagnosed with BPD (use of supplemental oxygen or 
respi[INVESTIGATOR_158728] 36 weeks postmenstrual age)  
3. Postmenstrual age ≥36 weeks at study enrollment  
4. Treatment with invasive mechanical ventilation at enrollment 
without planned tracheal extubation within 7 days  after 
enrollment  
5. Tracheal aspi[INVESTIGATOR_195927] a pathogenic GNR 
bacteria ( eligible organisms listed in section 3.4.3)  within 7 
days of beginning the study phase –  this testing will be 
performed during the screening phase and must be met to 
participate in the phase 1 trial or observational cohort  
6. Parental/guardian permission (informed consent).  
Exclusion Criteria  
1. Serum creatinine >0.4mg/dL within [ADDRESS_232798] s renal function 
3. Congenital or acquired hepatobiliary disease that adversely affects liver function  
4. Treatment with a systemic antibiotic  within 7 days prior to 
enrollment  
5. Treatment with a potentially nephrotoxic medication (see list in 
Appendix A) , excluding diuretics , within 48 hours prior to 
enrollment  
 
   
   
   xii 
6. Treatment with a continuous infusion of a neuromuscular 
blocker ( see list in Appendix B ) within 48 hours prior to  
enrollment  
7. Known intolerance to aminoglycoside antibiotics  
8. Current treatment with high frequency or other oscillating 
mechanical ventilation 
9. Presence of a cancer diagnosis  
10. Maternal family history of early onset hearing loss defined as 
the need for an assistive hearing device prescribed before 30 
years of age  
11. Persistent endotracheal tube leak >20%.  
12. Any investigational drug use (as part of an FDA  approved IND 
protocol) prior to enrollment.  
13. A subject who, in the judgement  of the Investigator, is not an 
appropriate candidate for this research study . 
Number of Subjects  
 Up to  103 infants will be enrolled in this  study  to produce up to 24 
infants with evaluable trial data and up to 28 participants in the 
observational cohort. The Children’s Hospi[INVESTIGATOR_195936].  
Study Duration  Each subject’s participation will last  from enrollment until hospi[INVESTIGATOR_7954]. The phase [ADDRESS_232799] up to 14 days . 
The entire study is expected to las t up to 3  years.  
Study Phases  
Screening Phase  
 
 
 
 
 
Study Phase  
Phase 1 Trial  
 
 
  
 
 
 
 
 
 
Observational  (non-
treated)  Cohort   Potential subjects will be screened using daily census logs and the 
protocol inclusion and exclusion criteria. Infants who meet study 
eligibility criteria will be enrolled  if a parent or guardian consents to 
once -weekly  collection s of a screening tracheal aspi[INVESTIGATOR_195926] . If a 
screening culture is positive for a pathogenic GNR , the infant will be 
eligible to participate in the phase 1 trial or observational (non -
treated) cohort , but can be enrolled in only one . 
 
The phase [ADDRESS_232800] up to 14 days, with each infant receiving a  
specified dose of tobramycin solution for inhalation every 12 hours , 
administered via vibrating mesh nebulizer. The  drug dose ( 78mg , 
150mg , 216mg, or 300mg) will be determined as per the i nter-
patient dose escalation 3+3 design protocol. If the 300mg dose 
level is completed without evidence of safety concerns (i.e., 
stoppi[INVESTIGATOR_195937]), up to [ADDRESS_232801].  For infants 
enrolled in the phase 1 trial , tracheal aspi[INVESTIGATOR_195938], 16s sequencing, and cytokine level 
measurement will be collected ≤48 hours and 14 days after 
receiving the final dose of inhaled tobramycin.  Infants enrolled in 
the observational cohort  will undergo tracheal aspi[INVESTIGATOR_195939] ≤48 hours  after completing the 14 -day study  phase. Infants 
in both cohorts will undergo respi[INVESTIGATOR_195940] 
≤48 hours  after completing the study phase.  
Safety Evaluations  The primary  study endpoint of the phase 1 trial is a safety outcome 
defined as the occurrence of any of the following:  
• Trough serum tobramycin level (measured [ADDRESS_232802] administered dose) ≥1µg/mL  
• Increase in serum creatinine level by ≥0.3mg/dL above the pre-
trial level 
• Increase in serum creatinine >1.5 -fold above the pre- trial level 
• Urine output <0.5mL/kg/hr for 12 hours  
• Any serious adverse event  possibly attribu table to the study drug 
 
Additional exploratory secondary safety endpoints are : 
• New onset or worsened coughing associated with a change in 
respi[INVESTIGATOR_82219] (SpO 2 <80% for >10 seconds; need for 
increase in FiO 2 by >20%)  
• Obstruction of the endotracheal tube requiring tube replacement  
• Unplanned tracheal extubation 
• Desaturation (SpO 2 <80% for >10 seconds) during 
administration of inhaled tobramycin  
• Rates of pre -discharge failed audiology examinations  
• Rates of n ew intra -patient microbial resistanc e to tobramycin  
Efficacy  Evaluations  The exploratory secondary efficacy endpoints  are: 
• Tracheal aspi[INVESTIGATOR_195934]  
• Change in tracheal aspi[INVESTIGATOR_195941] (CFU) counts measured by [CONTACT_120154], quantitative 
culture  
• Change in the following measures of administered respi[INVESTIGATOR_81407]: fraction of inspi[INVESTIGATOR_1401] ( FiO 2), ventilator mean 
airway pressure (MAP), respi[INVESTIGATOR_195942] (FiO 2 x MAP)  
• Change in the following measures of hypoxemia (SpO 2<80%): 
Intermittent hypoxemia ( events lasting 10s -3min), prolonged 
hypoxemia ( events lasting >1min), and daily proportion of time in 
hypoxemia  
• Change in tracheal aspi[INVESTIGATOR_195931] , neutrophil/WBC 
ratio,  and patterns in the airway microbiome  
• Change in dynamic lung compliance and airway resistance  
 
   
   
   xiv 
Pharmacokinetic  
Evaluations  Blood and tracheal aspi[INVESTIGATOR_195943] (PK) 
analyses will be collected. Patient specific PK parameters will be  
calculated using log -linear regression based on plasma peak and 
trough tobramycin concentrations .  
 
Population PK analys es will be conducted using nonlinear mixed 
effects modeling.  Mean population PK parameters (clearance, 
volume of distribution) will be estimated using the first -order 
conditional estimation with interaction method.  A 2-compartment 
model with first order absorption will be utilized based on prior 
knowledge of inhaled tobramycin pharmacokinetics.  
Statistical and Analytic 
Plan  All subjects entered into the phase  1 trial will be included in the 
primary safety analysis. The primary study outcome, listed above 
under “Safety Evaluations ,” will be evaluated as a dichotomous 
outcome based on the presence of any of the listed outcomes.  A 
3+3 design will be followed to determine enrollment and trial 
progression based on the results of each infant’s safety analysis.  
DATA AND SAFETY 
MONITORING PLAN A 4-member independent data safety monitoring board (DSMB) 
consisting of [ADDRESS_232803] will 
monitor trial data, safety, progress throughout the trial . 
 xv   
   TABLE 1: SCHEDULE OF STUDY PROCEDURES  
Study Phase  Screening  Phase 1 Trial  Follow -up 
Study Days   0a 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15b >15 
Informed consent  X                  
Review inclusion & exclusion criteria  X                  
Pre-trial medical record review  X                  
Prior  & concomitant medications  X                  
Dispense study drug    X X X X X X X X X X X X X X   
Review current medications   X X X X X X X X X X X X X X X X  
Review all laboratory , imaging data  X X X X X X X X X X X X X X X X  
Continuous pulse oximetry   X X X X X X X X X X X X X X X   
Pulmonary mechanics 
measurements   X       X        X  
Tracheal aspi[INVESTIGATOR_337]  X X    X   5X   X    X 2X 2Xc 
Blood draw for laboratory testing  
- Serum tobramycin trough 
- Comprehensive metabolic paneld   X   X   X   X    X   
Blood peak/trough for PK          2X          
Collect blood sample during clinical 
draws for PK analysese   X X X X X X X X X X X X X X   
Assessment of respi[INVESTIGATOR_1413]   X X X X X X X X X X X X X X X X  
Adverse event assessment (daily)   X X X X X X X X X X X X X X X X  
Adverse event assessment (weekly)                   X 
Review clinical audiology testing 
results  X                 X 
Discharge medical record review                   X 
  Observational (non- treated) cohort    
Tracheal aspi[INVESTIGATOR_337]  X                X  
Continuous pulse oximetry   X X X X X X X X X X X X X X X   
Assessment of respi[INVESTIGATOR_1413]   X X X X X X X X X X X X X X X X  
Pulmonary mechanics 
measurements    X      X        X  
Review clinical audiology testing 
results  X                 X 
Discharge medical record review                   X 
a “Day 0” procedures to be completed ≤7 days prior to trial Day 1  
b “Day 15” procedures to be completed ≤ 48 hours after the final administered dose of inhaled tobramycin (phase 1 trial) or study day 14 (observational cohort)  
c Tracheal aspi[INVESTIGATOR_195944] 14 days after the final administered dose of inhaled tobramyc in or on the day of planned tracheal extubation, if earlier  
d Serum magnesium and phosphorus levels will be checked with the comprehensive metabolic panel on trial days 7 and 14.  
e Up to 6 blood samples (200µL per sample) for pharmacokinetic analyses (PK) will be collected per infant concurrent with clinically ordered blood draws.  
 page xvi   
    
   
 
 
Figure 1. Study enrollment and phases flow diagram.  
 
* Details of both the phase 1 trial and observational  (non- treated)  cohort will be discussed with eligible 
families during the consent conversations.  Eligible infants may participate in either cohort  but can be 
enrolled in only one cohort .  
  

 page xvii   
    
 
 
  
 
Figure 2. 3+3 dose escalation design schematic . MTD: maximum tolerated dose  
 
Up to 4 different dos ages  of tobramycin solution for inhalation will be investigated using the 
above 3+3 trial design ( 78mg, 150mg, 21 6mg, and 300mg; all administered every 12 hours for 
up to 14 days) . If the 300mg dose level is completed in 3 participants and none show evidence 
of a toxic response, up to 3 additional infants will be enrolled to receive to receive 300mg. The 
trial will be stopped if 2 of the additional infants receiving 300mg develop a toxic response and the 216mg dose will be used as the maximum tolerated dose in subsequent trials.    
 A toxic response is defined as the occurrence of any of the following safety endpoints  during the 
14-day phase 1 trial  (see individual subject and full study stoppi[INVESTIGATOR_186179] 5.2.4 and 
5.2.5 for more detail s): 
• Trough serum tobramycin level (measured [ADDRESS_232804] administered dose) 
≥1µg/mL  
• Increase in serum creatinine level by ≥0.3mg/dL above the pre-trial level1-3 
• Increase in serum creatinine >1.5 -fold above the pre- trial level1-3 
• Urine output <0.5mL/kg/hr for 12 hours1-3 
• Any serious adverse event possibly attri butable to the study drugb 
 
 
b The likelihood an adverse event is attributable to a study intervention will be defined as outlined in section 8.3.  

   
   1 
1 BACKGROUND INFORMATION AND RATIONALE  
1.1 Introduction  
The objective of this phase 1, 3+[ADDRESS_232805] evidence of a pathogenic Gram -
negative rode ( GNR) bacteria detected by [CONTACT_196088][INVESTIGATOR_195926].  
 1.2 Burden of bronchopulmonary dysplasia (BPD)  
BPD is the most common and consequential complication of prematurity . BPD affects 
approximately 50% of extremely preterm infants, is a strong risk factor for life- long 
cardiopulmonary and neurodevelopmental impairment, and is a leading pediatric cause of 
disability -adjusted life years lost.
4-7 Disease acuity in BPD , defined by [CONTACT_77637][INVESTIGATOR_195945] 36 weeks postmenstrual age (PMA ), predicts the degree of 
childhood impairment. Very preterm infants treated with invasive mechanical ventilation at 
36 weeks PMA (grade 3 BPD) are 5 times more likely to undergo  tracheostomy than very 
preterm infants with less severe disease .8 Over 60% of very preterm infants with grade [ADDRESS_232806] (dysbiosis) have been implicated as 
inflammatory triggers and important risk factors in the development and exacerbation of 
BPD.
10-[ADDRESS_232807] colonization by a pathogenic GNR organism is associated with a 2- fold 
increase in the rates of supplemental oxygen use at 36 weeks PMA and  discharge to 
home.11 In an analysis of  121 very preterm infants receiving mechanical ventilation at 36 
weeks PMA in the newborn and infant int ensive care unit ( N/IICU ) at the Children’s Hospi[INVESTIGATOR_47775] ( CHOP ), airway colonization with a GNR bacteria was associated with a 6-
fold increase in the odds of death or need for home supplemental oxygen therapy (adjusted 
odds ratio 6.2, 95% CI 1.8- 21).[ADDRESS_232808] commonly 
cultured G NR (30% of study infants) and was independently associated with increased risk 
for death or prolonged oxygen therapy (adjusted odds ratio 4.9, 95% CI 1.1- 22).[ADDRESS_232809] to systemically administered agents, inhaled antibiotics may maximize intra -
pulmonary drug concentrations, optimize pharmacokinetic  indices, and substantially reduce 
   
   2 
systemic exposure and toxicity. Inhaled tobramycin has been shown to effectively decrease 
pathogenic bacterial density in the airways, reduce pulmonary exacerbation frequency, and 
improve the quality of life and lung function in patients  with cystic fibrosis (CF) and non -CF 
bronchiectasis whose respi[INVESTIGATOR_195946] P. aeruginosa .15,16 Owing to the 
favorable risk:bene fit ratio, inhaled antibiotics are  also gaining popularity for other disease 
states such ventilator associated tracheobronchitis and pneumonia.17-[ADDRESS_232810]  
This study will utilize t obramycin solution for inhalation USP ([LOCATION_002] Pharmacopeia) . 
Tobramycin solution for inhalation USP is a sterile, clear, slightly yellow, non -pyrogenic, 
aqueous solution with the pH and salinity adjusted specifically for administration by 
[CONTACT_196094]. The chemical formula for tobramycin, USP is C 18H37N5O9 and the molecular 
weight is 467.52. Tobramycin, USP is  O-3-amino -3-deoxy -α-D-glucopyranosyl -(1→4) -O-
[2,6-diamino- 2,3,6 -trideoxy -α-D-ribo-hexopyranosyl -(1→6)] -2-deoxy -L-streptamine. The 
structural formula for tobramycin, USP  is shown in Figure 3. Each 5mL ampule contains 
300mg of tobramycin, USP and 11.25mg sodium chloride in sterile water. Sulfuric acid and 
sodium hydroxide are added to adjust the pH to 6. Nitrogen is used for sparging. All 
ingredients meet USP requirements. The formulation contains no preservatives.  
 
 
Figure 3. Structural formula for Tobramycin, USP  
 Tobramycin is a member of the aminoglycoside class of antibiotics. This class exert their 
antimicrobial activity by [CONTACT_53167] 30s subunit of the bacterial ribosome  and inhibiting 
protein synthesis, thus inhibiting growth and division of the bacteria. Aminoglycosides, 
including tobramycin are not absorbed enterally, therefore must be administered locally  
such as through nebulization or intravenous instillation.  
 
1.6 Findings from Clinical Studies  
1.6.1 Human pharmacokinetics  
Wang et al. studied the pharmacokinetics (PK) of tobramycin solution for inhalation in 
patients aged between [ADDRESS_232811] -order absorption model.21 Serum tobramycin levels reached near 
undetectable  trough levels 10 -12 hours after administration in children <7 years of age 
(Figure 4A) and peak serum tobramycin levels were below 1-2 µg/mL in all children <2years 
of age ( Figure 4B).21 Relative bioavailability in patients between 6 months and 7 years of 
age increased with age ( i.e. younger  children demonstrated lower  serum concentration 
levels) .[ADDRESS_232812] dosing at the infection site (lung).21 They  concluded that P. 
aeruginosa eradication rates and safety profiles in patients aged <7 years were similar to 
older patients and that no dose adjustment is needed in young children.21 

   
   3 
 
Figure 4. (A) Visual prediction check of the final PK model for children <7 years of age. Open circles are  observed 
concentrations. Central solid line is the median of observed concentrations, dashed lines are the 2.5% and 97.5% 
quantile of observed concentration s. The central shaded area represents the 95% confidence interval (CI) of the 
median of the simulated profiles and the upper and lower 95% CI  for the 2.5% and 97.5% quartiles, respectively. (B)  
Effect of age on steady -state exposure of tobramycin using simulations (semi -log view). PK profiles of 1000 subjects 
were simulated per clearance per age group. Central solid lines represent the median concentration; shaded areas 
frame  the 50% (25th-75th percentile) and 90% (5th-95th percentile) of the subjects. Horizontal dashed lines represent 
the safe serum trough threshold utilized by [CONTACT_196095]. Top panel shows simulation s using data form 3 trials22-
24 and the bottom simulation data from an additional trial25. 
 
In a separate study, Rosenfeld et al.  f ound that peak serum concentrations occurred  
approximately 1 hour (range 0.5 -2hr) after administration of  300mg of tobramycin solution 
for inhalation to children aged 0.6 -5.8 years ( Figure 5).26 The average peak  serum 
concentration of 0.6µg/mL (range: <0.2 to 1.2 µg/mL ) was within the acceptable, safe trough 
range for intravenous  tobramycin . Serum tobramycin levels reached negligible values in 
most study patients within 4 hours after  administration ( Figure 5).26  
Figure 5. Serum tobramycin concentration – time profiles in 19 children (age range 0.6- 5.8yr) treated with 300mg of 
inhaled tobramycin.  Time shown along the x -axis indicates minutes since administration of the inhaled dose. In 3 
patients, all levels were below the detectable limit of 0.2 µg/mL (dotted line).26 

   
   4 
[IP_ADDRESS]  Clinical Studies in Older Children (>6 years) and Adults  
Tobramycin solution for inhalation is approved by [CONTACT_196096] A dministration for  
the treatment of respi[INVESTIGATOR_195947] P. aeruginosa in patients with CF  who are at 
least 6 years of age.  The CF Foundation “strongly recommends” the use of inhaled 
tobramycin for the treatment of “initial or new growth of P. aeruginosa from an airway 
culture.”16 They rate the certainty of benefit with this therapy as “ high,” and estimate the net 
benefit as “substantial.”16 An expert panel from the European CF Society also recommends 
the use of inhaled tobramycin for the treatment of newly acquired P. aeruginosa infection.27 
Multiple controlled trials ( Table 2) conducted in older children and adults support the safety 
and efficacy of inhaled tobramycin in this population. Several of these trials, combined with 
data from younger children ( Table 3, section [IP_ADDRESS]) were included in a recent Cochrane 
review . This meta -analysis  support s the use of inhaled tobramycin in children with CF who 
have culture proven respi[INVESTIGATOR_195948] P. aeruginosa.[ADDRESS_232813] ions due to P. 
aeruginosa and other GNR  bacteria in non- CF bronchiectasis ( Table 2), chronic obstructive 
pulmonary disease (COPD) , and ventilator -associated infections.18,29- 31 
 
[IP_ADDRESS]  Clinical Studies in Infants and Young Children  (≤ 6 years)  
Several clinical trials have demonstrated the safe use of inhaled tobramycin in infants (<1 
year of age) and young children ( Table 3). The Australian Cystic Fibrosis Bronchoalveolar  
Lavage (BAL) study enrolled 170 infants (mean age 3.6  ± 1.6 months at enrollment).40,41 In  
 Table  2. Published randomized trials  evaluating  tobramycin solution for inhalation (TSI) in older childr en (≥6 years)  or adult 
patients with P. aeruginosa  present in the sputum.  
Author / 
Year  Dose / 
Frequency  Disease  Participants ’ 
ages Study duration  Trial 
size Key findings  
Ramsey 
199932 300mg  BID CF ≥ 6 years  
 24 weeks 
(cycled 28 days 
on, 28 days off) N=520  • Improved pulmonary 
function 
• Decreased 
hospi[INVESTIGATOR_195949] 
200433 300mg BID  CF 6-15 years  56 weeks (cycled 28 days 
on, 28 days off)  N=184 • Decreased hospi[INVESTIGATOR_195950] 
198934 80mg  TID CF 7-24 years  32 months  N=27  • Stability in pulmonary 
function, controls 
showed decline  
Smith 
198935 600mg  TID CF Mean age 
17.3 ± 6.1 
years  12 weeks  N=22  • Improved symptoms, decrease in bacterial 
density  
Ramsey 
199336 600mg  TID CF Mean age 
17.1 ± 1.3 
years  12 weeks 
(cycled 28 days on, 28 days off)  N=71  • Improved pulmonary 
function 
Scheinberg 
200537 300mg  BID non-CF 
bronchiectasis  ≥ 18 years  
 12 weeks 
(cycled 14  days 
on, 14 days off)  N=41  • Improvements in 
respi[INVESTIGATOR_195951] 
200538 300mg  BID non-CF 
bronchiectasis  38-75 years  6 months  N=30  • Decrease in the 
number of hospi[INVESTIGATOR_124021]  
• Shorter duration of 
hospi[INVESTIGATOR_195952] 
200039 300mg  BID non-CF 
bronchiectasis  Mean age 67 
± 13 years  28 days  N=74  • Decreased sputum 
bacterial load 
• Improvement in 
respi[INVESTIGATOR_1856]  
• No new bacterial 
resistance  
   
   5 
 
total, 46 of the  study infants were treated with 2 weeks of systemic antibiotic therapy 
followed by [CONTACT_196097] (300mg twice daily) for 2 months.40,41 No adverse effects 
secondary to inhaled tobramycin were reported in the trial.41 A recent retrospective cohort 
study reported the use of inhaled tobramycin in  32 infants (<1 year of age) with CF.47 The 
mean age at initiation was 4 months, with 72% aged <[ADDRESS_232814] treatment.47 The 
median dose of inhaled tobramycin was 80mg (IQR 80- 120); 4/32 (22%) were treated for 14 
days and the remainder (78%) were treated for [ADDRESS_232815] (83%) were free  of P. 
aeruginosa by [CONTACT_196098] (53%) remained free 6 months after 
treatmen t.47 Overall, inhaled tobramycin was well tolerated.47 Only 1 patient required 
therapy discontinuation owing to cough.47  
 
The limited available data from infants without CF support the safe use of inhaled 
tobramycin when administered to infants  who:  (1) do not have pre -existing renal disease , Table  3. Published randomized trials  of tobramycin solution for inhalation (TSI) in young children with P. aeruginosa  
present in the sputum.  
Author / 
Year  Dose / 
Frequency  Disease  Eligible 
participant s’ ages Study duration  Trial 
size Key findings  
Ratjen 
201924 300mg BID  CF 3 months to >7 
years  28 days with 
optional cross -
over for 
additional 28 
days  N=51  • Effective eradication of 
early P. aeruginosa 
infection  
• Favorable safety profile  
Ratjen  
201025 300mg BID  CF ≥6 months (42% of 
cohort  aged <6 
years)  28 days vs. 56 
days  N=88  • >90% of participants free of P. aeruginosa after 1 month of treatment  
• Favorable safety profile  
Gibson 2003
42 300mg BID  CF 6 months to 6 years  (29% of the 
cohort aged <3 years)  28 days  N=21  • Reduced density of P. 
aeruginosa in the lower 
airway  with TSI  
• Reassuring mean peak 
(1.0 ± 0.4 mcg/mL) and 
trough (0.4 ±  0.5 mcg/mL) 
serum tobramycin levels  
• No change in renal or 
auditory function with TSI 
Treggiari 
201143 300mg BID  CF 1-12 years  
(30% of the cohort 
aged 1-3 years)  28 days +/- oral 
ciprofloxacin. Treatment provided either  
quarterly or only with positive 
sputum culture 
over 18 months  
period  N=304  • No benefit with addition of 
oral ciprofloxacin  
• Minimal emergence of 
antibiotic resistant strains  
• No difference in renal, liver, or audiometric 
function in between trial 
arms 
Taccetti  
201244 300mg BID  CF >1 year  
(35% in the TSI 
arm aged ≤5 
years)  28 days TSI + 
oral ciprofloxacin 
vs. inhaled colistin + oral ciprofloxacin N=223  • TSI with similar efficacy as colistin  
• 65% free of P. aeruginosa 
6 months after TSI + ciprofloxacin therapy  
• No serious adverse 
events  
Wiesemann 
199845 80mg BID  CF >4 years  12 months  N=22  • Shorter time to 
conversion to P. 
aeruginosa negative 
respi[INVESTIGATOR_195953]  
201346 300mg BID  CF 0-18 years (7% <2 
years of age)  
 28 days  N=58  • TSI vs. inhaled Na-
colistimethate resulted in  
similar eradication of P. 
aeruginosa (80 -90%)  
   
   6 
and (2) are not  receiving concurrent  nephrotoxic intravenous antibiotics. A single center 
retros pective cohort study from the University of Oklahoma identified [ADDRESS_232816] of the described patients received 
300mg t wice daily with a low interquartile range of 60mg twice daily.48 Although the authors 
do not report respi[INVESTIGATOR_195954], they indicate inhaled tobramycin continues to be one 
therapy used for the treatment of respi[INVESTIGATOR_195955].  The authors report that t wo infants developed acute 
kidney injury  while receiving inhaled tobramycin (one after 5 days  of therapy , the other after 
17 days of therapy).48 Both received 300mg twice daily during the treatment course.48 One 
received intravenous gentamicin within 48 hours of initiating tobramycin (last gentamicin 
trough 1.3mcg/mL)  and the second had  recently undergone surgical palliation for  complex 
congenital heart disease.48 Both infants had detectable serum tobramycin trough levels (1.9 
and 3.2 mcg/mL).48 Two additional case reports describe the use of inhaled tobramycin 
(300mg twice daily)  in preterm infants without CF (32 weeks’ gestation, 2.5 months of age 
treatment; 34 weeks’ gestation, 1 month of age at treatment).49,50 Although both infants 
developed detectable tobramycin levels  above the goal trough range, they also both 
received concurrent IV doses of nephrotoxic antibiotics (including IV tobramycin in one 
case) and were diagnosed wi th pre-existing renal disease.49,50 Finally, analysis of data from 
the Pediatric Health Information Sy stem (PHIS) database suggests that inhaled tobramycin 
in used some infants with severe BPD. A recent study found that 3% ( 93/3252)  of very 
preterm infants with severe BPD (gestational age <32 weeks; <1 year of age at treatment) 
in the dataset were prescrib ed inhaled tobramycin between 2007- 2016 . Taken together, 
these data indicate  that: (1) inhaled tobramycin is used in clinical practice to treat  infants  
(some as young as 3 months of age)  with and without CF –  including those with severe 
BPD, and (2) administration of inhaled tobramycin at doses ≤ 300mg,  coupled with close 
monitoring of serum levels , is likely to be safe in  preterm infants diagnosed with severe 
BPD who are ≥36 weeks PMA at the time of treatment .  
 
1.6.2 Potential toxicity  with inhaled tobramycin  
[IP_ADDRESS]  Nephrotoxicity  
Nephrotoxicity was not seen during clinical trials of tobramycin solution for inhalation in children or adults . However , nephrotoxicity has been associated with aminoglycosides as a 
class. Aminoglycosides in systemic circulation are eliminated via glomerular filtration  and 
can induce toxicity to the proximal tubule. The acute tubular necrosis that can occur  is most 
commonly  mild and reversible (owing to the ability of the proximal tubules to regenerate).
51 
The considerably reduced serum exposure to tobramycin with inhalational administration 
substantially lower s the risk of acute kidney injury ( AKI).52 At present, evidence suggesting 
a possible link between inhaled tobramycin and  AKI in infants and young children is limited 
to case reports.48,53 In nearly all of these cases, there was evidence of renal dysfunction 
prior to the initiation of inhaled tobramycin and /or concomitant treatment with additional 
nephrotoxic agents.48,53  
 [IP_ADDRESS]  Ototoxicity  
Ototoxicity, as measured by [CONTACT_196099], did 
not occur in any of the clinical trials evaluating tobramycin solution for inhalation in children 
or adults.
54 Moreover, there is no convincing evidence that inhaled tobramycin administered 
without concurrent systemic aminoglycoside therapy results in ototoxicity i n pediatric 
   
   7 
patients . A multicenter European trial comparing a 28- day and a 56- day course of inhaled 
tobramycin (300mg twice daily) in children as young as 6 months of age with CF did not find 
a single case of hearing loss during extended follow -up.25 Similarly, a 2018 Cochrane 
review evaluating long- term use of inhaled tobramycin in CF patients did not identify a 
single case of hearing loss among 258 study participants.15 In a multicenter Australian 
study evaluating audiometric function before and after treatment with inhaled tobramycin 
(treatment duration ranged 59- 119 days) in 142 children <6 years of age, only 1 child 
receiving both inhaled tobramycin and intermittent intravenous tobramycin developed mild, 
unilateral sensorineural hearing loss.55 This child inadvertently received a 300mg 
(21.3mg/kg) IV tobramycin dose, instead of a nebulized dose, in addition to the concurrently prescribed IV tobramycin dose.
55 
 
In addition to the lack of data linking inhaled tobramycin to ototoxicity in young children, the 
overwhelming abundance of data indicate that systemically administered aminoglycosides 
do not cause hearing loss in infants when used as directed. A single center study of 2347 
infants found no increased risk of an abnormal audiology evaluation among inf ants who 
received gentamicin compared to those who did not.56 Two studies, including one 
evaluating 84,808 hospi[INVESTIGATOR_151405], found no relationship between the presence of 
sensorineural hearing loss and the cumulative aminoglycoside dose, the average daily 
dose, or the duration of administration.57,58  
 
One small observational study (n=81) reported an increased risk of sensorineural hearing 
loss in infants who received systemic aminoglycoside therapy duri ng concurrent treatment 
with a neuromuscular blocking agent.59 Whether this finding represents  a true toxicity  or is 
confounded by [CONTACT_196100]. Notably, this study found no 
association between the dosage or duration of systemic aminoglycoside therapy and the 
risk for sensorineural hearing when the antibiotic was used in infants who were not co -
treated with a paralytic agent.59 Out of an abundance of caution, this phase 1 trial will 
exclude infants treated with a neuromuscular blocker within 48 hours of enrollment.  
 
Genetic risk for aminoglycoside induced ototoxicity: Homoplasmic  A1555G and 
C1494T mutations in the 12s mitochondrial rRNA gene may predispose to aminoglycoside-induced hearing loss.
60,61 These mutations are present in approximately 0.2% of infants.62 
Although clinical testing for these maternally -inherited mutations is not yet performed in an 
anticipatory manner, avoiding use of aminoglycosides in patients with a maternal family 
history of early onset sensorineural hearing loss may be  beneficial.  
 Vestibular toxicity following treatment with  aminoglycoside antibiotics: Vestibular 
toxicity, leading to symptoms such as dizziness, imbalance, and nausea, is a rare 
complication (~2%) of systemically administered aminoglycosides reported in adults.
[ADDRESS_232817] of care for very preterm infants with BPD in the CHOP N/IICU , all infants 
enrolled in the phase [ADDRESS_232818] 2 years of life.  
 
   
   8 
[IP_ADDRESS]  Additional adverse reactions  
Data from randomized , placebo- controlled trials of inhaled tobramycin in children and adults 
with CF indicate inhaled tobramycin is generally well tolerated. In 2 studies inclusive of 258 
patients who received inhaled tobramycin (300mg twice daily with alternating periods of 28 
days on and off treatment for 24 weeks), voice alteration (13% vs. 7% in the placebo group) 
and tinnitus without loss of hearing (3% vs 0% in the placebo group) were the only adverse experiences reported by [CONTACT_196101].
54 Changes in voice/cry are not expected in this study of infants receiving invasive 
mechanical ventilation. Additional reported adverse events that may be related to inhaled 
tobramycin use include cough, increased  sputum production, bronchospasm, and 
hemoptysis . Allergic reactions and anaphylaxis are possible adverse reactions  of any drug . 
 
1.7 Rationale for drug dosages and duration under investigation  
The recommended dose of inhaled tobramycin in children with CF who are ≥[ADDRESS_232819] evaluated the safety and efficacy  of this regimen in children as 
young as 6 months of age with CF and not found evidence of toxicity.25,26,55,67 At present, 
there are no universally established dosing recommendations for inhaled tobramycin in 
children without CF. Published reports in young children without CF describe s afe 
administration with doses ranging from 80- 300mg every 12 hours.48,68,69 A consensus 
summary from the So ciety of Infectious Disease Pharmacists recommends a dose of 80mg 
every 12 hours for acute exacerbations of non- CF bronchiectasis.17  
 
This trial will investigate  up to 4 different dos es of inhaled tobramycin: 78 mg, 150mg, 
216mg, and 300mg  – each administered every 12 hours . A dose of 80mg has been shown 
to be safe and effective in children <6 years  of age .45-47 This trial will investigate an initial 
dose of 78mg rather than 80mg (a 2.5% decrease in dose) to enable accurate dilution from 
a 300mg/5mL drug vial using a 3mL syringe (see section 7.1.3 for further details on drug 
dosing and aliquoting).  
 The FDA -approved dose of intravenous (IV) tobramycin for infants is 7.5mg/kg per day. 
This IV dose far exceeds the amount of drug expected to reach the systemic circulation with 
nebulized therapy ( Table 4 ). During nebulization, l ess than 15% of the administered drug  
reaches the airways. This equates to ≤12mg of tobramycin for each 78 mg dose.  The 
available data indicate that <5% of inhaled tobramycin that reaches the airways is absorbed into systemic circulation , resulting in serum  peak levels that are approximately 95% lower 
with inhaled versus  intravenous administration.  Based on these data, w e anticipate that a 
starting dose of 78mg of inhaled tobramycin administered every 12 hours will not  generate 
detectable serum tobramycin tr ough levels or result in toxicity . This study will investigate 
doses as high as 300mg twice daily  if the 3+3 dose escalation design does not raise 
concern for potential toxicity at lower doses. This maximum possible dose was chosen as 
the available PK data indicate there is no need to decrease the dose of inhaled tobramycin 
below the recommended  dose of 300mg when treating children <6 years of age  (see 
section 1.6.1) .
[ADDRESS_232820]  that 
longer treatment courses may not be necessary.  Therefore, a 14-day course is expected to 
   
   9 
generate sufficient data to evaluate dose safety and tolerability and provide preliminary 
efficacy data to inform the design of possible future phase 2 and phase 3 trials.   
 
1.8 Compliance Statement  
This study will be conducted in full accordance of all applicable CHOP Research Policies 
and Procedures and all applicable f ederal and state laws and regulations including 45 CFR 
46, 21 CFR Parts 50, 54, 56, 312, and the Good Clinical Practice (GCP) : Consolidated 
Guideline approved by [CONTACT_8639]  (ICH). Adverse 
event reporting will be targeted, so that potential adverse events arising from the use of 
inhaled tobramycin (for example, inhalational side- effects as well as renal adverse events) 
will be reported, while other adverse effects attributed to the underlying disease or clinical care will not be reported. All epi[INVESTIGATOR_48478].  
 
The investigators will perform the study in accordance with this protocol, will obtain 
informed consent, and will report unanticipated problems involving risks to subjects or 
others in accordance with the CHOP  IRB Policies and Procedures and all federal 
requirements. Collection, recording, and reporting of data will be accurate and will ensure 
the privacy, health, and welfare of research subjects during and after the study.  
 
[ADDRESS_232821] evidence of a pathogenic GNR 
detected by [CONTACT_196088][INVESTIGATOR_195926].   
 
2.1 Primary Objective  
The primary objective of this study  is to determine the maximum  well-tolerated dose of 
tobramycin solution for inhalation (selected between 78mg , 150mg, 216mg, and 300mg 
administered twice daily) administered to very preterm infants with BPD who are actively 
receiving invasive mechanical ventilation and have evidence of a pathogenic GNR detected by [CONTACT_196088][INVESTIGATOR_195926].   
 
2.2 Secondary Objectives  
The secondary, exploratory  objectives are to: 
• Evaluate the association between the dose of inhaled tobramycin, plasma  
tobramycin pharmacokinetics,  and peak  tracheal aspi[INVESTIGATOR_195934]. Table 4 . Anticipated maximum peak serum tobramycin concentrations and daily IV dose equivalence for the 
drug dosage under investigation in this phase 1 trial  
Inhaled tobramycin  
dose  Anticipated maximum peak  serum 
concentration (per dose)a Approximate IV dose equivalen ts based on 
anticipated systemic exposureb  
78mg 0.31 µg/mL  0.24 mg/kg/day  
150mg  0.6 µg/mL  0.46 mg/kg/day  
216mg 0.86 µg/mL  0.66 mg/kg/day  
300mg  1.2 µg/mL  0.92 mg/kg/day  
a Calculated using data from Rosenfeld et al. indicating maximum peak serum tobramycin levels were 
≤1.2µg/mL following treatment with 300mg of inhaled tobramycin in young children.26 
b Intravenous (IV) dose equivalents calculated based on the anticipated maximum peak serum 
concentrations shown in the table and observed peak serum concentrations of 26.0 ± 2.1µg/mL after 
administration of a 10mg/kg intravenous dose of tobramycin in pediatric patients.70    
   
   10 
• Compare the change (pre vs. post study ) in tracheal aspi[INVESTIGATOR_195956] (CFU) counts measured by [CONTACT_196090], (1) between 
participants in the phase 1 trial and untreated infants in the observational cohort, 
and (2) between trial participants  stratified by [CONTACT_196102].  
• Compare the longitudinal change in measures of administered respi[INVESTIGATOR_1413] 
(FiO 2, ventilator mean airway pressure, and respi[INVESTIGATOR_195942]) during the 
14-day study period, (1) between participant s in the phase 1 trial and observational 
cohort  and (2) between trial participants stratified by [CONTACT_196091].  
• Compare changes (pre vs. post treatment) in tracheal aspi[INVESTIGATOR_195931] , 
neutrophil /WBC ratio , and patterns in the airway microbiome , stratified by [CONTACT_196092].  
• Change in the following measures of hypoxemia (SpO 2<80%): Intermittent 
hypoxemia ( events lasting 10s -3min), prolonged hypoxemia ( events lasting >1min), 
and daily proportion of time in hypoxemia  
 
• Compare the longitudinal change in dynamic lung compliance, airway resistance, 
peak expi[INVESTIGATOR_10229], and CO 2 elimination  during the 14- day study period, (1) 
between participants in the observational cohort and phase 1 trial and (2) between 
trial participants stratified by [CONTACT_196103].  
3 INVESTIGATIONAL PLAN  
3.1 General Schema of Study Design  
This study is an  open- label, phase 1 , inter-patient 3+3 dose escalation feasibility trial. A 
prospective, observational  (non- treated)  cohort of eligible infants will also be enrolled and 
outcomes compared to the trial participants. The study phases are depi[INVESTIGATOR_6517] [ADDRESS_232822] begin the phase 1 tri al or observational (non- treated) 
cohort 14- day study period within [ADDRESS_232823] e that is positive for a pathogenic GNR (Figure 6). Infants whose screening culture (s) 
is/are negative for a pathogenic GNR bacteria will continue to be screened weekly for as 
long as they meet study eligibility criteria. This plan for serial screening is consistent with 
the regular surveillance used to monitor for Pseudomonas infection in children with CF and 
reflects the increasing risk of developi[INVESTIGATOR_007] a GNR respi[INVESTIGATOR_195957].10,71,[ADDRESS_232824] up to 14 days, with each infant receiving an inhalational dose of  
tobramycin solution administered every 12 hours via vibrating mesh nebulizer. The dos e 
(78mg , 150mg, 216mg, or 300mg) will be determined as per the 3+3 design protocol 
(Figure 2). During the investigational drug trial , each infant will undergo blood and tracheal 
   
   11 
aspi[INVESTIGATOR_195958] -specified time points  to 
assess dosage safety and potential efficacy. Continuous pulse oximetry will be performed 
beginning 24- 48hr prior to initiating the study drug and continued until completion of the 14-
day trial. Review of c linical data and assessment for adverse e vents will be conducted  daily 
throughout the 14 -day trial.  
  3.1.3 Observational (non -treated) Cohort 
Infants enrolled in the observational (non- treated) cohort  will undergo 14 days of clinical 
data collection. During the study phase, respi[INVESTIGATOR_195959] 1 and 7. Respi[INVESTIGATOR_195960] ≤48 hours  after the final study day as indicated in section 3.1.4. Pulse oximetry 
will be performed throughout the 14 -day study period.  
 
 
Figure 6. Diagram of study phases. GNR, Gram -negative rod. *  Details of both the phase 1 trial and observational (non-
treated) cohort will be discussed with eligible families during the consent conversations. Eligible infants may participate in 
either cohort but can be enrolled in only one cohort.  Infants will enter into one of the two study cohorts within [ADDRESS_232825]. For infants enrolled in the phase 1 
trial, tracheal aspi[INVESTIGATOR_195961] s 
will be collected ≤ 48 hours and 14 days (or on the day of planned tracheal extubation, if 
earlier) after receiving the final dose of inhaled tobramycin.  For infants enrolled in the 
observational cohort, a tracheal aspi[INVESTIGATOR_195962] ≤ [ADDRESS_232826] and final 
respi[INVESTIGATOR_195940] ≤48 hours  after the final study day.  
 

   
   12 
3.2 Allocation to Treatment  and Masking  
Infants who satisfy the inclusion and exclusion criteria and a parent or guardian consents 
for the infant to participate in the phase 1 trial will be allocated to receive up to 14 days of 
tobramycin solution for inhalation at the dosage determined by [CONTACT_941] 3+3 trial design. Drug 
dosage will not be masked ( blinded). 
 
3.[ADDRESS_232827]  tracheal aspi[INVESTIGATOR_195963] 
14 days  after completing the final administered dose of inhaled tobramycin. For infants who 
participate in the observational (non- treated) cohort, clinical data will be collected daily for 
14 days beginning after enrollment . Respi[INVESTIGATOR_195964] (day 0 for the trial participants, day 1 for the observational c ohort) , study day 7, and 
≤48 hours  after the final study day .    
  
3.3.2 Total Number of Study Sites/Total Number of Subjects Projected  
Study site:  Neonatal/infant intensive care unit at the Children’s Hospi[INVESTIGATOR_6684].  
 
Up t o 103  infants will be enrolled in the study to produce up to 52 evaluable subjects  (phase 
1 trial + observational cohort) . These numbers are estimated according to the enrollment 
flow diagram shown in Figure 7. Up to  26 infants  are expected to receive the study drug to 
produce up to 24 infants with evaluable trial data. These numbers for the phase 1 trial 
account for the 24 infants needed to enroll up to 6 infants per each of the 4 evaluated 
doses (assum ing 1 infant with a toxic response per dose level) plus withdrawal of up to 2 
infants (~10%) prior to receiving 14 drug doses  for reasons other than a toxic response. We 
will target a minimum of 12 infants in the observational cohort. Enrollment in the observational (non- treated) cohort will be capped at 28 infants.  
 
 
Figure 7. Flow diagram of estimated maximum enrollment numbers 
 
3.4 Study Population  
3.4.1 Inclusion Criteria  
1. Male or female infants born <32 weeks’ gestation 

   
   13 
2. Diagnosed with BPD (use of supplemental oxygen or respi[INVESTIGATOR_158728] 36 
weeks postmenstrual age)  
3. Postmenstrual age ≥36 weeks at study enrollment  
4. Treatment with invasive mechanical ventilation at enrollment without planned 
tracheal extubation within 7 days  after enrollment  
5. Tracheal aspi[INVESTIGATOR_195927] a pathogenic GNR bacteria ( see list of eligible 
organisms in section 3.4.3) within 7 days of beginning the study phase –  this testing 
will be performed during the screening phase and must be met to participate in the 
phase 1 trial or observational cohort  
6. Parental/guardian permission (informed consent).  
 
3.4.2 Exclusion  Criteria  
1.    Serum creatinine >0.4mg/dL within [ADDRESS_232828] s renal function 
3. Congenital or acquired hepatobiliary disease that adversely affects liver function  
4. Treatment with a systemic antibiotic  within 7 days  prior to enrollment  
5. Treatment with a potentially nephrotoxic medication (see list in Appendix A) , 
excluding diuretics , within 48 hours prior to  enrollment  
6. Treatment with a continuous infusion of a neuromuscular blocker ( see list in 
Appendix B ) within 48 hours prior to  enrollment  
7. Known intolerance to aminoglycoside antibiotics  
8. Current treatment with high frequency or other oscillating mechanical ventilation 
9. Presence of a cancer diagnosis  
10. Maternal family history of early onset hearing loss defined as the need for an 
assistive hearing device prescribed before 30 years of age  
11. Endotracheal tube leak >20%.  
12. Any investigational drug use (as part of an FDA approved IND protocol) prior to 
enrollment.  
13. A subject who, in the judgement of the Investigator, is not an appropriate candidate 
for this research study.  
 Subjects that do not meet all of the above criteria may not be enrolled. Any violations of 
these criteria must be reported in acc ordance with IRB Policies and Procedures .  
3.4.[ADDRESS_232829] be cultured from a tracheal 
aspi[INVESTIGATOR_195965] 7 days prior to enrollment to meet trial eligibility : 
• Pseudomonas aeruginosa 
• Klebsiella species  
• Enterobacter species  
• Stenotrophomonas maltophilia  
• Escherichia coli  
• Acinetobacter baumannii  
• Serratia marcescens  
[ADDRESS_232830] of 
main study procedures can also be found in Table 1 (page xiv). 
 
   
   14 
4.1 Screening Phase  
Census documents in the CHOP N/ IICU will be reviewed bi -weekly during the study period 
to identify potentially  eligible subjects. For subjects likely to be eligible, medical  records will 
be reviewed using the  inclusion and exclusion criteria. S tudy participation and enrollment 
criteria will first be discussed with the subject’s attending physician. After obtaining approval 
of the attending physician, the parent(s) or guardian(s) will be approached,  and the details 
of the study will be discussed. First, consent will be obtained to collect a screening tracheal 
aspi[INVESTIGATOR_195966] a pathogenic 
Gram -negative rod organism is not identified. The parent  or guardian will be informed that 
the results of  the tracheal aspi[INVESTIGATOR_195926] (s) will be used to determine eligibility for the 
phase 1 trial of inhaled tobramycin  and the observational cohort . Details of the two study 
cohorts  will be discussed during the initial consent conversations. However, a second 
consent discussion for participation in the inhaled tobramycin trial or observational (non -
treated) cohort will take place for those in whom the tracheal aspi[INVESTIGATOR_195967] 
a pathogenic GNR.  After learning of the study goals, procedures, risks and benefits, the 
parent (s) of eligible infants will be invited to participate in the phase 1 trial or observational 
cohort  and if interested,  informed consent will be obtained. Informed consent will be 
obtained prior to any study related procedures being performed.  All screening culture 
results will be disclosed to families of enrolled infants. See section 9.6 for a description of 
the informed consent procedure.  
 
4.2 Observational (non- treated) cohort  
The medical record of each infant enrolled in the observational cohort will be reviewed 
regularly until hospi[INVESTIGATOR_195968]- specified clinical data. Each infant in the 
observational cohort will also undergo respi[INVESTIGATOR_195969] s 
1, 7 and ≤48 hours after completing the 14 -day study period (see section 4.3.3) . A tracheal 
aspi[INVESTIGATOR_195970] ≤48 hours after completing the 14 -day study period 
(see section 4.3.2) . Oxygen saturation data (SpO 2) will be recorded using continuous pulse 
oximetry. To collect this data, a research pulse oximeter will be placed in addition to the 
pulse oximeter used for clinical monitoring. This second device will enable reliable data 
collection,  storage, and analysis. Nursing and medical staff will be instructed to use the 
clinical oximeter for all clinical monitoring.   
 
4.3 Phase 1 Trial of Tobramycin Solution for I nhalation  
The phase 1 trial of inhaled tobramycin will utilize a 3+3 inter -patient dose escalation design 
(Figure 8). The safety and tolerability of up to 4 different doses of tobramycin will be 
evaluated: 78mg, 150mg, 216mg, and 300mg. Each dose will be administered every 12 
hours  for up to 14 days via vibrating mesh 
nebulizer. If the 300mg dose level is 
completed in 3 participants and none show 
evidence of a toxic response, up to 3 additional infants will be enrolled to receive to receive 300mg. The trial will be stopped 
if 2 of the additional infants receiving 
300mg develop a toxic response and the 
216mg dose will be used as the maximum 
tolerated dose in subsequent trials. The 
study procedures utilized to monitor drug 
safety and efficacy are listed in Table 5. 
 
 
 
Figure 8. 3+3 dose escalation design schematic . MTD: maximum 
tolerated dose  

   
   15 
 
 
4.3.1 Blood draws  
All blood samples required as part of this research protocol will be collected by [CONTACT_196104] l stick, 
venipuncture, or from an indwelling catheter  (e.g., arterial line) by [CONTACT_196105], in adherence with  standardized, written hospi[INVESTIGATOR_195971] . Samples will then  
be transferred to the CHOP clinical or research laborator ies for analysis . Required blood 
sample volumes per laboratory test are: serum tobramycin level (0.5mL), comprehensive 
metabolic panel (1mL), PK blood samples (200µL). In addition  to the pre- specified study 
blood draws , 200µL of blood will be collected for PK  analyses on up to [ADDRESS_232831] the safety of enrolled subjects, study team members, in consultation with nursing 
staff and the medical  team , will ensure blood volume extraction (for clinical + research 
purposes) does not exceed the maximum allowable weight -based limits specified by [CONTACT_196106] (no more than 5 mL/kg drawn in a single day).  
 Table 5. Study procedures utilized to monitor drug safety, tole rability, and efficacy  for participants in the phase 1 trial.  
  Study Day  Follow -up 
Procedure  0a 1 4 7 10 14 All 
(1-14) 15b 28C 
Tracheal aspi[INVESTIGATOR_337]  X  X – after 
7th dose  X – after 
14th dose     X X 
Test:           
Quantitative culture  X       X X 
Cell count differential  X       X X 
Cytokine levels  X   X    X X 
16s sequencing  X   X    X X 
Tobramycin leveld   X 5X X X    
Blood draw   X – after 
2nd dose  X – after 
7th dose  X – after 
14th dose  X – after 
20th dose  X – after 
28th dose     
Test:           
Tobramycin troughe  X X X X X    
Comprehensive 
metabolic panelf  X X X X X    
Tobramycin peakg    X      
Random tobramycin 
levelsh       X   
Continuous pulse 
oximetry  X      X   
Pulmonary mechanics 
measurements  X   X    X  
Daily medical record 
review        X   
Weekly medical 
record reviewi        X X 
a “Day 0” procedures to be completed ≤ [ADDRESS_232832] study drug dose . The quantitative tracheal aspi[INVESTIGATOR_195972]. Prior to initiating study drug therapy, 
one additional tracheal aspi[INVESTIGATOR_195973] 16s sequencing.  
b “Day 15” procedures to be completed ≤[ADDRESS_232833] (in- person) guidance 
of a study team member. Our research team has extensive experience coordi nating 
endotracheal sample collection for microbiome and cytokine analyses. In most cases, the 
timing of tracheal aspi[INVESTIGATOR_195974], clinical suctioning of the endotracheal (ET) tube. 
However, if the collection of a tracheal aspi[INVESTIGATOR_195975] a set time (e.g. , timed 
after an inhaled tobramycin dose)  and routine clinical suctioning will not occur at that time, a 
research  only collection will be performed . Clinical and research suctioning of the 
endotracheal tube will be performed as described in the paragraph below . In the CHOP 
N/IICU, infants with BPD who are receiving invasive mechanical ventilation undergo routine 
endotracheal suctioning several times per day. Most undergo clinical suctioning at least 
every 3 hours, and often more frequently (as much as every 20- 30 minutes) owing to the 
high secretion burden in infants with GNR bacteria in the airways.  
Tracheal aspi[INVESTIGATOR_195976] a suction catheter just proximal to the end of the ET tube (length of ET tube is indicated at the bedside for all intubated 
infants). Tracheal secretions will be aspi[INVESTIGATOR_38105] a sterile Lukens trap. After tracheal 
secretion collection and removal of  the suction catheter from the ET tube, the suction 
catheter will be cleared by [CONTACT_6149][INVESTIGATOR_19860] 1mL of sterile 0.9% saline (note: saline should not be instilled directly into the ET tube). This is the standard clinical procedure used to collect 
airway samples in the CHOP N /IICU. A minimum of 0.5mL of tracheal fluid will be collected 
– resulting in a total of approximately 1.5mL of fluid in the Lukens trap after flushing the 
suction catheter with 1mL of saline. In our experience, this procedure provides  suffic ient 
sample recovery for the specified analyses (see sections 5.1.2 and 5.1.3) and is consistent 
with tracheal aspi[INVESTIGATOR_195977].
73-[ADDRESS_232834] clinical stability.76 A sterile (new) suction catheter will be 
used for all microbiological sampling as per unit protocol . Tracheal aspi[INVESTIGATOR_195978] a new suction catheter or the existing in-line 
suction catheter.  
4.3.3 Respi[INVESTIGATOR_195979] 3 timepoints: study entry (day 0 for 
participants in the phase 1 trial, day 1 for participants in the observational cohort), on study 
day 7, and ≤[ADDRESS_232835] for up to 4 hours. The Respi[INVESTIGATOR_195980], if present, or directly to the endotracheal 
tube if not, and the “y” connector of the ventilator tubing. This device is FDA approved for 
use in infants (510 (k) K091459). The Respi[INVESTIGATOR_195981]3 continuously monitor s several 
mechanical and physiological respi[INVESTIGATOR_195982], dynamic 
lung compliance, airway resistance, peak expi[INVESTIGATOR_10229], and carbon dioxide elimination. 
These data will be downloaded to a dedicated, password protected s tudy computer 
following each recording session. Respi[INVESTIGATOR_195983].  
 
   
   17 
The Respi[INVESTIGATOR_195981]3 monitor sensor adds a negligible amount of dead space to the 
ventilator circuitry (0.8mL, <3% of inspi[INVESTIGATOR_195984]) and 
has been successfully used without adverse effects in infant studies,77,78 including those 
conducted i n the CHOP N/IICU (IRB 12 -008686). The same procedure for collecting 
respi[INVESTIGATOR_195985] 1 trial and those 
enrolled in the observational cohort.  
 
4.3.4 Continuous pulse oximetry  
Continuous peripheral oxygen s aturation (SpO 2) measurements will be obtained beginning 
24-48hr prior to initiating the study drug and continued throughout the 14- day study period 
using a Masimo Rad- G pulse oximeter. A [ADDRESS_232836]  will be periodically reviewed until hospi[INVESTIGATOR_195986]:  
 
• Occurrence of adverse events that may be related to the investigational drug 
• Weekly abstraction of respi[INVESTIGATOR_195987] (including all 
culture results and use of any antimicrobials)  
• Weekly abstraction of respi[INVESTIGATOR_195988] (drug name [CONTACT_70820])  
• Discharge review of respi[INVESTIGATOR_195989], audiology screening results, medications prescribed for home use, and discharge disposition  
 
For the infants enrolled in the phase 1 trial, t racheal aspi[INVESTIGATOR_195990] 2 
separate time points during the follow -up phase (as shown in Table 5). The first time point 
will be within [ADDRESS_232837] to complete the described 
laboratory testing (one sample will be  analyzed in the  clinical laboratory – see section 
[IP_ADDRESS]; and the second is used for research laboratory analyses –  see section [IP_ADDRESS]) . For 
infants enrolled in the observational (non- treated) cohort, a single tracheal aspi[INVESTIGATOR_195991] 48 hours after study day 14, or at the time of 
extubation,  if earlier. The procedures described in section 4.2.2 will be used to obtain these 
samples.  The final respi[INVESTIGATOR_195992] 
≤[ADDRESS_232838] Completion/Withdrawal  
Subjects will be withdrawn from the phase 1 trial for any of the following reasons:  
 
• Occurrence of any of the primary safety endpoints listed in section 5.2.1  
• Initiation of an intravenous  antibiotic, continuous infusion of a neuromuscular 
blocking agent, or a new cancer diagnosis  
• Tracheal extubation  
o Infants who have not yet completed the phase 1 trial and are re- intubated 
≤48 hours after extubation may restart the trial procedures at the same stage 
as when the extubation occurred . 
o Infants will not resume the investigational drug trial if 2 instances (c ombined) 
of endotracheal tube obstruction or unplanned extubation occur during the 
14-day phase 1 trial.  
 
Infants enrolled in the observational (non- treated) cohort will discontinue respi[INVESTIGATOR_195993] 14- day 
study period and not resumed within [ADDRESS_232839] for reasons of safety (i.e. , presence 
of adverse events) or for administrative purposes . Early withdrawal will not result in any 
prejudi ce to the subject’s care. It will be documented whether or not each subject completes 
the clinical study. If the Investigator becomes aware of any serious, related adverse events after the subject completes or withdraws from the study, they will be recorded in the source 
documents and on the case report forms  and reported to the IRB and DSMB as described 
in section 8.  
 4.7.[ADDRESS_232840] 
1 serum tobramycin trough, a comprehensive  metabolic panel , and collection of 2 tracheal 
aspi[INVESTIGATOR_195994] – unless these 
procedures are refused by [CONTACT_196107]. Laborator y testing may be repeated at 
the discretion of the research and medical teams for safety purposes . Review of the 
medical record will also continue as appropriate unless refused by [CONTACT_114788].  
 
4.7.2 Addition of Trial Participants after Early Terminat ion 
Additional research subjects will be added to the phase 1 trial as per the 3+3 design (Figure 8). In addition, s ubjects who are removed early from the trial for reasons other than 
   
   19 
a toxic response or safety concern related to the investigational drug will be replaced 1:1 if 
fewer than 14 doses  of inhaled tobramycin were administered. U p to 2 s ubjects  total and  no 
more than  1 per dose level , who receive ≥14 doses  of inhaled tobramycin, are removed 
early from the trial  for reasons other than a toxic response or safety concern related to the 
investigational drug , and do not meet criteria for any of the primary tolerability endpoints will 
inform progression through the 3+[ADDRESS_232841] receive the full 14- day treatment course (28 doses) of the dose that 
is ultimately defined as the maxi mum tolerated dose at the end of this  trial. Participants will 
be added as needed to fulfill this requirement. If the 300mg dose level is completed in [ADDRESS_232842] assessment of drug 
tolerability and PK. The trial will be stopped if 2 of the additional infants receiving 300mg (2 out of 5 or 2 out of 6) develop a toxic response. In that event, the 216mg dose w ill be 
considered the maximum tolerated identified in this study.  
 
[ADDRESS_232843] Review  
[IP_ADDRESS]  Screening Phase  
The following data will be abstracted from the medical record during the screening phase:  
• Date of birth  
• Gestational age  
• Birth weight  
• Sex 
• Race/ethnicity  
• Prenatal exposure to corticosteroids  
• Postmenstrual age at study enrollment  
• Weight, length, and head circumference at enrollment  
• Respi[INVESTIGATOR_1413] (including settings and FiO 2) at enrollment  
• Currently prescribed medications  and those administered with 7 days prior to 
enrollment (name, dos e, route, and interval ).  
• Prior microbiological data from birth through enrollment, including culture results and 
antibiotic exposures (drug, duration, dates of exposure)  
• Results of any prior audiological examination or testing 
• Diagnoses present in the active problem list  
 
[IP_ADDRESS]  Phase [ADDRESS_232844] will be reviewed as follows throughout the phase 1 trial : 
• Daily review of the medical record and discussion with the medical team, nursing, 
and respi[INVESTIGATOR_195995]  
   
   20 
• Daily review of weight, vital sign s (heart rate, blood pressure, oxygen saturation), 
and fluid balance (including urine output) r ecorded by [CONTACT_196108] (EPIC) flow sheet  
• Daily respi[INVESTIGATOR_195989] (mode of ventilation, settings, FiO 2, and calculated 
respi[INVESTIGATOR_195942]: mean airway pressure x FiO 2) recorded in EPIC  
• Daily review of admin istered medications (name, dos e, route, and interval)  
• Daily review of any clinically ordered laboratory tests and radiographic imaging.  
 
[IP_ADDRESS]  Observational (non -treated) cohort  
The medical records of infants who are enrolled in the observational cohort will be reviewed 
daily for 14 days beginning after enrollment . Respi[INVESTIGATOR_195989]  (mode of ventilation, 
settings, FiO 2, and calculated respi[INVESTIGATOR_195942]: mean airway  pressure x FiO 2) will 
be abstracted from EPIC.  
 
[IP_ADDRESS]  Follow -up Phase  
The medical record will be reviewed from the end of the 14-day phase 1 trial /observational 
period until hospi[INVESTIGATOR_195996]:  
• Weekly review of the medial record to assess for serious  adverse events (only 
infants enrolled in the phase 1 trial)  
• Results of all audiology evaluations conducted prior to hospi[INVESTIGATOR_2345]  
• Date, age, and postmenstrual age at hospi[INVESTIGATOR_2345]  
• Medications and respi[INVESTIGATOR_195997]  
 
5.1.2 Continuous pulse oximetry  
A research pulse oximeter (see section 4.3.4) will be used throughout the 14- day study 
period to measures reliable SpO 2 levels. Oximeter monitoring will begin 24- 48 hours prior 
beginning the phase 1 drug trial to establish baseline values.  
 
5.1.3 Clinical D ata W arehouse  
Routine physiologic monitoring data (heart rate, oxygen saturation, blood pressure) will be obtained from the clinically prescribed bedside multiparameter monitor on phase 1 trial and 
observational cohort study participants . This data  will be downloaded from CHOP data 
warehouse and analyzed by [CONTACT_3476]. These data will be stored on the CHOP 
research server.  
 5.1.4 Clinical Laboratory Evaluations  
[IP_ADDRESS]  Screening phase  
Tracheal aspi[INVESTIGATOR_195998] :  
• Tracheal aspi[INVESTIGATOR_195999]  
• Tracheal aspi[INVESTIGATOR_196000], this sampling will be performed even in infants with a recent clinically obtained 
tracheal aspi[INVESTIGATOR_196001].  
 
   
   21 
[IP_ADDRESS]  Phase 1 Trial  
Blood sampling will be performed for the following laboratory evaluations : 
• Serum tobramycin level monitoring  (note:  this sampling differs from blood 
tobramycin levels used for the PK analyses described in section 5.1. 4.2) 
• Serum electrolytes  
• Liver function assessment  
• Renal function assessment  
Tracheal aspi[INVESTIGATOR_196002] : 
• Tracheal aspi[INVESTIGATOR_195999]  
• Tracheal aspi[INVESTIGATOR_196003] 5.1. 3.1 and 5.1. 3.2 (and shown in Table 6 ) will be 
performed in the clinical laboratory at CHOP. All laboratory tests performed in the CHOP 
clinical lab meet the regulatory requirements  of the State Health Department, CLIA 88, 
FDA, AABB, CAP and JCAHO. The timing of collection of these tests is outlined in Table 5 
and in sections 4.2 and 4.3 
 
Table 6: Clinical Laboratory Tests  
 
[IP_ADDRESS]  Follow- up Phase  
For the phase 1 trial participants, tracheal aspi[INVESTIGATOR_196004] -up phase ( ≤48 hours 
after receiving the final dose of inhaled tobramycin and 14 days after receiving the final 
dose of inhaled tobramycin or on the day of planned tracheal extubation, if earlier) : 
• Tracheal aspi[INVESTIGATOR_196005]  
• Tracheal aspi[INVESTIGATOR_196006], tracheal aspi[INVESTIGATOR_196007]- up phase, ≤48 hours after day 14 of the 
observation period.  
5.1.5 Research Laboratory Evaluations 
[IP_ADDRESS]  Tracheal Aspi[INVESTIGATOR_196008] : 
• Tobramycin level  
• Cytokine level analysis (including: IL 1β, 6, 8, 17A/F, 18, 22, 23, TNF -α, MIF, IFN -γ) 
• 16s microbial sequencing 
 
Additional tracheal aspi[INVESTIGATOR_196009] -up phase for the 
following laboratory analyses: 
• Cytokine level analysis (including: I L 1β, 6, 8, 17A/F, 18, 22, 23, TNF- α, MIF, IFN -γ) Category  Tests  
Drug monitoring  
Metabolic panel  
 
Liver function tests  
Renal function tests  
Microbiology  
Body fluid cell count  Serum tobramycin  
Serum sodium, potassium, chloride, bicarbonate, glucose, calcium, total 
protein, albumin. Magnesium and phosphorus will be collected on day 7, 14  
SGOT/AST, SGPT/ALT, total Bilirubin, alkaline phosphatase  
BUN, creatinine  
Quantitative culture of tracheal aspi[INVESTIGATOR_196010]  
   
   22 
• 16s microbial sequencing 
 
Cytokine level analyses will be performed in the CHOP Translational Core Laboratory. 
Owing to inevitable variation in dilution during the collection process, cytokine level will be 
normalized to total protein levels in the tracheal aspi[INVESTIGATOR_196011].73,79 Tracheal aspi[INVESTIGATOR_196012]. 
Whether tracheal aspi[INVESTIGATOR_196013] a lack of available evidence. We will explore differences in the study results with and without 
urea correction for dilution and compare the results to laboratory controls. The 16s 
microbial sequencing will be performed in the laboratories of the CHOP/Penn Microbiome 
Program.  All laboratory procedures will be conducted using validated assays. The results of 
these laboratory tests will be reported as part of the data collection process for the research study, but will not appear in the medical record nor be used to make clinical decisions.   
 
[IP_ADDRESS]  Blood Sampling for Pharmacokinetic Analyses  
Blood (0.2mL) will be collected for pharmacokinetic analyses at 2 set time points on da y 7 
plus up to 6 random collections coincident with clinically obtained draws . The lower limit of 
quantification for serum tobramycin concentrations in the CHOP clinical laboratory is 0. 6 
µg/mL. Based on this quantification limit, we  anticipate that the ma jority of subjects will 
have clinically undetectable trough and/or peak levels, limiting the ability to characterize 
serum pharmacokinetics. Measurement of blood plasma tobramycin levels will be 
performed at the University of [LOCATION_012] College of Pharmacy  using high- performance liquid 
chromatography tandem mass spectrometry  (HPLC- MS/MS) . This will enable quantification 
of drug levels down to a level of 50 -100 ng/mL and facilitate estimation of patient -specific 
pharmacokinetics.  Individually identif iable will be removed from samples and the samples 
will be labeled with unique identifiers. The CHOP study team will be able to link the unique 
identifiers to individually identifiable information, but the individually identifiable information 
will not be available to outside researcher s. 
 
5.1.[ADDRESS_232845] respi[INVESTIGATOR_196014]. Measurements will be performed at 3 time points:  at study entry ( study day 
0 for infants enrolled in the phase 1 trial, study day 1 for infants enrolled in the 
observational cohort) , study day  7, and ≤[ADDRESS_232846] 4 hours and coincide with a period of qui et sleep. The NM3 
monitor  is FDA approved for use in infants (510 (k) K091459). The Respi[INVESTIGATOR_195981]3 
monitor  will be used to collect data on the following endpoints: dynamic compliance (mL/cm 
H2O), peak expi[INVESTIGATOR_10229] (L/min), airway resistance (cm H 2O/L/sec), an d carbon dioxide 
elimination  (mL/min). These data will be downloaded to a dedicated, password protected 
study computer following each recording session. For this analysis, only results obtained 
from mandatory, ventilator driven non- pressure support breaths  will be used.  
 5.2 Safety Evaluations  
5.2.1 Primary composite safety endpoint  
The primary objective of this trial is to assess the safety and tolerability of up to 4 different 
dose levels  of tobramycin solution for inhalation in preterm infants receiving invasive 
mechanical ventilation with a tracheal aspi[INVESTIGATOR_195927] a pathogenic GNR . 
Following the 3+3 trial design ( Figure 8), tolerability of each dose will be defined as no 
   
   23 
more than 1 in 6 infants per dos e level  developi[INVESTIGATOR_196015] 14- day trial:  
 
• Serum tobramycin trough (measured 11 hours after the prior  dose) ≥ 1µg/mL  
Serum tobramycin trough levels will be performed as per the schedule outlined in section 
4.2. Quantification of serum tobramycin levels will be performed in the CHOP Clinical 
Laboratory as described in section 5.1. 3. Current standards (including pharmacy 
guidelines at CHOP  for conventional dosing strategies ) and manufacturer labelling for 
intravenous tobramycin recommend maintaining serum tobramycin trough levels 
<2µg/mL.80 Out of an abundance of caution, any measured trough value ≥ 1µg/mL  will 
define a toxic response.  
• Increase in serum creatinine level by ≥0.3mg/dL above pre -trial level 
• Increase in serum creatinine >1.5 -fold above the pre- trial level 
• Urine output <0.5mL/kg/hr for 12 hours  
 
These  3 measures of reduced kidney function indicate stage 1 ( the least severe stage) 
of acute kidney injury (AKI) as defined by  [CONTACT_196109] (KDIGO) practice guidelines.1-3 Serum creatinine levels will be measured  as 
per the schedule outlined in section 4.2. Quantif ication of  serum creatinine levels will be 
performed by [CONTACT_196110] 5.1.2.  
 
Nursing staff monitor urine output of all infants in the CHOP N/IICU throughout each day 
by [CONTACT_196111]. Typi[INVESTIGATOR_897], this is performed every 3 hours, coinciding 
with nursing care  times. As per routine clinical care, “combo” diapers containing both 
urine and stool will be utilized when calculating total urine output. Data on urine output is 
recorded in the electronic medical record (EPIC) and will be reviewed by [CONTACT_196112] s prior to the administration of each investigational drug dose.       
 
• Any serious adverse event  possibly attribut able to the study drug .  
 
The occurrence of adverse events identified by [CONTACT_196113] (in addition to those described above) will be monitored throughout the trial and reported 
as described in section 8.  A serious adverse event will constitute a toxic response.  
 
5.2.2 Secondary exploratory safety endpoints  
Additional exploratory safety endpoints that will be recorded are:  
 
• New onset or worsened coughing associated with a concomitant drop in SpO 2 to <80% 
for >10 seconds , need for an increase in FiO 2 by [CONTACT_196114] >20% , or need 
clinical recovery using positive pressure support delivered via manual bag ventilation  
• Obstruction of the endotracheal tube requiring tube replacement  
• Unplanned tracheal extubation 
• Desaturation (SpO 2 <80% for >10 seconds) during administration of inhaled t obramycin 
• Rates of pre -discharge failed audiology examinations  
• New intra -patient antimicrobial resistance  
 
5.2.3 Limitations of A udiology Testing in Hospi[INVESTIGATOR_057] I nfants  
Inhaled tobramycin therapy in infants with BPD is not expected to result in ototoxicity. 
Ototoxicity, as measured by [CONTACT_196099], did 
   
   24 
not occur with tobramycin inhalation solution therapy during clinical studies .54 Moreover, 
intravenous aminoglycoside use has not been shown to result in hearing loss in preterm 
infants when used as directed (see section [IP_ADDRESS] for a  discussion of these studies).  
 Some studies evaluating inhaled tobramycin  in older children and adults performed 
audiometric testing prior to and after completing a drug course and did not find significant 
evidence of persistent hearing loss .
55,81,[ADDRESS_232847] measures which include Auditory Brainstem Response (ABR) or Otoacoustic Emissions (OAE), must be used to screen newborns and 
infants for hearing loss. Newborns with tracheostomy or ventilator dependency may be 
screened later due to their complex medical conditions. Patient awake state, movement and electrical interference from equipment can impact testing. In addition, chronic fluid or 
abnormal middle ear pathology, common in this population, may cause hearing loss that can be transient or chronic in nature.   
 Complex medical presentations common in this population and environmental influences 
may impact initial test results, supporting the need for continued audiologic follow -up. One 
study of 78 preterm infants with BPD found auditory brainstem response (ABR) 
abnormalities in 22% of participants.
83 All subjects who failed the ABR demonstrated 
normal hearing by [CONTACT_196115] (VROA) at 8 -12 months.83 
Notably, 10 of 14 infants (71%) who failed the gold standard VROA at follow -up had a 
normal ABR at hospi[INVESTIGATOR_2345].83 Another study of 216 hospi[INVESTIGATOR_196016] (a -TEOAE), 
automated auditory brainstem response (a- ABR), and conventional brainstem auditory 
evoked potential (BAEP/ABR).[ADDRESS_232848] specificity (71- 91%) and 
poor positive predictive value (9- 25%) when compared to repeat testing BAEP/ABR 
conducted 2 -3 months later.84 Finally, BAEP/ABR can only detect hearing abnormalities 
occurring between 0.5- 4hz.[ADDRESS_232849] frequencies >4hz.85  
 
The American Academy of Pediatrics (AAP) recommends that all infants at risk of hearing 
loss should undergo subsequent screening by 24 to 30 months of age. Importantly, 
recommendations for audiologic follow -up should be customized based on individual patient 
risk factors and likelihood of delayed- onset hearing loss. Accordingly, t he Joint  Committee  
on Infant  Hearing (JCIH)  recommend  beginning in 2019 that that all infants  with a risk 
indicator  for hearing loss who pass  the initial newborn hearing screen should be referred for 
an audiologic  assessment  by 9 months  of age.86 
 
Owing to challenges of completing audiologic testing in preterm infants who are receiving 
intensive care (e.g., ongoing invasive mechanical ventilation) and obstacles that contribute 
to obtaining these tests in this population (infants with severe BPD in the CHOP N/IICU 
require a median of [ADDRESS_232850] can be successfully 
performed – regardless of the eventual result), all audiologic screening in study participants 
will be performed prior to hospi[INVESTIGATOR_196017] N/IICU. 
All study infants will undergo pre- discharge ABR and OAE testing as well as tympanometry 
as indicated by [CONTACT_196116]. The results of these evaluations will be recorded 
as part of the study data. The rate of failed pre- discharge hearing tests in a recent cohort of 
infants who received care in the CHOP N/IICU and were similar to those eligible for this 
study was 36%.87 Based on these data, a rate of pre- discharge hearing screening 
abnormalities ≥50% among the infants treated with inhaled tobramycin will trigger adverse 
event reporting to the IRB and FDA. In addition, the rates of failed pre -discharge 
audiometric evaluations will be compared between infants who participate in the 
   
   25 
investigational drug trial and those who are enrolled in the study but do not participate in the 
drug trial (e.g., lack of GNR in the airway or parental refusal to participate in the phase 1 
trial). A statistically significant difference in the rates of failed evaluations between these 
two groups will also trigger adverse event reporting to the IRB and FDA.  
 
In the CHOP N/IICU, all infants with abnormal audiologic test results are referred for 
additional evaluations by [CONTACT_196117]. Consistent  with the above 
recommendations from the JCIH86, infants who attend the CHOP newborn follow- up 
program and pass their newborn hearing screening are also referred for repeat audiologic 
testing by [CONTACT_2669] [ADDRESS_232851] will be removed from the phase 1 trial and will not receive additional doses 
of the study drug i f he/she develops a toxic response defined as any of the followi ng: 
• Trough serum tobramycin level (measured [ADDRESS_232852] administered dose) ≥1µg/mL 
• Increase in serum creatinine level by ≥0.3mg/dL above the pre -trial level1-3 
• Increase in serum creatinine >1.5 -fold above the pre- trial level1-3 
• Urine output <0.5mL/kg/hr  for 12 hours1-3 
• Any other serious adverse event  possibly attribut able to the investigational drug  
 
Subjects may also be withdrawn from the  study  for reasons that do not meet the above 
criteria as described in section 4. 7. 
 If an infant commences the trial and the  primary medical team  subsequently chooses to 
prescribe a systemic antibiotic  (e.g., for the positive tracheal aspi[INVESTIGATOR_196018]/not present  at the time of enrollment), the infant will stop the 
phase 1 trial early. No additional doses of inhaled tobramycin will be administered but final 
labor atory testing will be performed.  
 
5.2.5 Study Stoppi[INVESTIGATOR_196019] 3+[ADDRESS_232853] develops a drug -related toxic 
response (any of the safety endpoints listed under section 5.2.1 ) at a single dosage level.  
Further enrollment will be stopped, but data analysis for those enrolled 
will continue until completed.   
 
                                                                                  Figure 9. 3+3 dose escalation design schematic . MTD: maximum 
tolerated dose 
 

   
   26 
5.3 Efficacy Evaluations  
Measures of potential drug efficacy will be assessed as secondary, exploratory endpoints. 
These will include the following outcomes:  
 
• Change (pre vs post treatment) in tracheal aspi[INVESTIGATOR_195941] (CFU) counts measured by [CONTACT_196118][INVESTIGATOR_196020] ≤7 days  prior to initiating  
inhaled tobramycin (as part of the screening procedures) , ≤48 hours after  completing 
the final drug dose, and 14 days after completing the final drug dose  (or on the day of 
planned tracheal extubation if earlier)  (see schedule under section 4. 3). For infants 
enrolled in the observational (non- treated) cohort, tracheal aspi[INVESTIGATOR_196021] ≤7 days  prior to initiating the 14- day observation period (as part of the 
screening procedures) and ≤[ADDRESS_232854] cytokine levels, and the RSS.  
• Tracheal aspi[INVESTIGATOR_196022]: (1) a single tracheal aspi[INVESTIGATOR_196023] 4, 
10, and 14, 11- hours after completion of the 8
th, 20th, and 28th doses respectively; and 
(2) 5 samples will be collected on trial day 7 , approximately 1-hour, 3-hours, 6 -hours, 9 -
hours, and 11 -hours  after completion of the 14th tobramycin dose (see section 4. 3) 
Tracheal aspi[INVESTIGATOR_196024]  (see section 5.1.3).  Tracheal aspi[INVESTIGATOR_196025] 90% of detected bacterial isolat es (MIC 90).90,91 
Longitudinal change in tracheal aspi[INVESTIGATOR_196026].  Correction for serum urea levels will be performed.   
• Longitudinal c hange in the following respi[INVESTIGATOR_196027] 14- day 
study period:  
o Fraction of inspi[INVESTIGATOR_1401] ( FiO 2) 
o Ventilator mean airway pressure (MAP)  
o Respi[INVESTIGATOR_195942] (MAP x FiO 2) 
 
FiO [ADDRESS_232855] pressure (MAP) are established clinical measures of respi[INVESTIGATOR_196028] . They characterize the amount of respi[INVESTIGATOR_1413] (supplemental 
oxygen and positive airway pressure) required to maintain cardiorespi[INVESTIGATOR_196029] . The res pi[INVESTIGATOR_195942] (RSS) is a 
   
   [ADDRESS_232856] of the oxygenation index (OI) owing to the infrequent availability of data on the  
partial pressure of arterial oxygen (PaO 2) in hospi[INVESTIGATOR_151405]. The RSS correlates 
well with OI in infants  receiving mechanical ventilation and is a useful predictor of poor 
respi[INVESTIGATOR_196030].92-94 FiO 2 and MAP values (measured by t he 
mechanical ventilator and reported on the ventilator graphical interface), are recorded at 
least hourly in the respi[INVESTIGATOR_196031] (EPIC). These 
data will be used to calculate daily, time -weighted values for FiO 2, MAP , and RSS. 
Longitudinal change in these respi[INVESTIGATOR_196027] 14 -day study 
period will be compared (1) between infants who participate in the phase 1 trial and 
those enrolled in the observational (non- treated) cohort, and (2) among participants in 
the phase 1 trial, stratified by [CONTACT_196103].  
 
Owing to the expected heterogeneity in lung disease and respi[INVESTIGATOR_196032], a protocolized ventilato r management algorithm 
will not be utilized during this study. However, routine practice in our unit is to wean 
FiO 2 in infants with BPD to maintain SpO 2 ≥90%. Most infants with BPD who require 
invasive respi[INVESTIGATOR_196033] a time- cycled, pressure- limited, 
volume- guarantee mode of ventilation that  deliver s 8-10mL/kg of tidal volume at 
mandated rates of 15- 25 breaths per minute. The Draeger V500 ventilator is used in all 
infants receiving acute care in the CHOP N/IICU who are prescribed intermittent 
mechanical ventilation. On this mode of support, the  ventil ator automatically adjusts the 
positive inspi[INVESTIGATOR_27111] (PIP) –  within set limits – to deliver the goal tidal volume. 
Change in the PIP along with any clinical adjustments in the positive end expi[INVESTIGATOR_22325] (PEEP) will be the primary determinant s of any observed changes in the 
delivered MAP. Only infants with an endotracheal tube leak ≤20% will be enrolled in this 
trial to avoid ventilator leak compensation and artificial inflation of the PIP levels.95 Of 
note, the Draeger V500 ventilator calculates  the endotracheal leak proportion during all 
modes of intermittent ventilation employed in our unit.  
 
• Change (pre vs post) in tracheal aspi[INVESTIGATOR_195931] , neutrophil/WBC ratio,  and 
patterns in the airway microbiome:  
Tracheal aspi[INVESTIGATOR_196034] ≤ 7 days prior to initiating inhaled tobramycin, ≤[ADDRESS_232857] microbiome will be assessed using 16s 
sequencing performed in the laboratories of the CHOP/Penn Microbiome Program. The 
following cytokine levels will be measured in tracheal aspi[INVESTIGATOR_26594]: IL 1β, 6, 8, 
17A/F, 18, 22, 23, TNF- α, MIF, IFN -γ. These analyses will be performed in CHOP 
Translational Core Laboratory . Tracheal aspi[INVESTIGATOR_196035]. Changes in  the observed patterns in the airway microbiome , 
neutrophil/WBC ratio,  and tracheal aspi[INVESTIGATOR_195931] (compared to the pre -
treatment baseline) will be assessed, stratified by [CONTACT_196119] (see 
section 6.3 for further details of the analytical plan).  For this phase 1 feasibility trial, we 
will evaluate the relative, intra -patient change in these measures  as the association 
between these m easures and clinical benefit in the study population is uncertain.  
• Longitudinal change in the following measures of respi[INVESTIGATOR_196036] 14-
day study period:  
o Dynamic compliance (mL/cm H 2O) 
o Peak expi[INVESTIGATOR_10229] (L/min),  
   
   [ADDRESS_232858] resistance (cm H 2O/L/sec)  
o Carbon dioxide elimination (mL/min).  
 
The Respi[INVESTIGATOR_195981]3 respi[INVESTIGATOR_196037] 4 hours  periods at study entry , on study day  7, and ≤48 hours  after completing the 
14-day study period. These data will provide important information on the potential 
effects  of inhaled tobramycin on respi[INVESTIGATOR_4806]. 
 
• Longitudinal change in the following measures of hypoxemia (SpO 2<80%):  
o Intermittent hypoxemia (SpO 2<80% lasting for 10s -3min)  
o Prolonged hypoxemia (SpO 2<80% lasting for >1min)  
o Daily proportion of time with hypoxemia 
 
Daily frequency of intermittent and prolonged hypoxemic events are established, real -
time indicators of cardiorespi[INVESTIGATOR_196038].96 Cumulative burden of hypoxemia 
predicts the severity of childhood neurodevelopmental delay.97 These data will be 
recorded continuously throughout the study using a research pulse oximeter that will be placed in addition to the clinical multiparameter monitor. Nursing and medical staff will be instructed to use the clinically placed monitor for all care decisions.  
 5.4 Pharmacokinetic Evaluation  
Each infant participating in the phase 1 trial will undergo blood sampling on  day 7 to 
measure serum tobramycin peak and trough levels.  Up to 6 random blood samples (200µL 
per sample) will also be collected concurrent with clinical blood draw s. Based on prior 
studies, we anticipate that most trial participants, particularly those receiving the lowest dosages of inhaled tobramycin, will have serum trough levels  below the lower lim it of 
quantification in the clinical lab (0. 6µg/mL).
21,48,[ADDRESS_232859] 200µL of blood 
for high resolution measurement of  peak , trough and random plasma tobramycin levels as 
per section 6.3.4 . Blood samples collected for PK analyses will be stored at -80c in vials 
labelled with a study ID number only. Sample batches will be shipped to and subsequently processed at the University of [LOCATION_012] College of Pharmacy. This laboratory has extensive 
experience with high- resolution drug level testing and has established assays  for 
tobramycin.  
 
6 STATISTICAL CONSIDERATIONS  
6.1 Primary Endpoint  
The primary study endpoint  is a composite safety endpoint. The presence of any of the 
following events occurring at any timepoint during the 14- day phase 1 trial will define a toxic 
drug response:  
• Trough serum tobramycin level (measured [ADDRESS_232860] administered 
dose) ≥ 1µg/mL 
• Increase in serum creatinine level by ≥0.3mg/dL above the pre-trial level 
• Increase in serum creatinine >1.5-fold above the pre- trial level 
• Urine output <0.5mL/kg/hr for 12 hours  
• Any serious adverse event  possibly attributable to  the investigational drug  
 
6.2 Secondary Endpoints  
Additional exploratory secondary safety endpoints  are: 
• New onset or worsened coughing associated with a change in respi[INVESTIGATOR_82219] 
(SpO 2 <80% for >10 seconds; need for increase in FiO 2 by >20%)  
   
   29 
• Obstruction of the endotracheal tube requiring tube replacement  
• Unplanned tracheal extubation 
• Desaturation (SpO 2 <80% for >10 seconds) during administration of inhaled 
tobramycin  
• Rates of pre -discharge failed audiology examinations  
• Rates of new intra -patient microbial resistance  to tobramycin  
o Bacterial antimicrobial sensitivities reported for the pre -treatment tracheal 
aspi[INVESTIGATOR_196039]. The presence of new -onset microbial  resistance to 
tobramycin within a patient – a change from susceptible to resistant by [CONTACT_196120] – will be recorded  
 
The exploratory secondary efficacy endpoints  are: 
• Tracheal aspi[INVESTIGATOR_195934]  
• Change in tracheal aspi[INVESTIGATOR_195929] (CFU) counts measured by [CONTACT_120154], quantitative culture  
• Longitudinal change in the following measures of administered respi[INVESTIGATOR_1413]: FiO
2, ventilator mean airway pressure (MAP), respi[INVESTIGATOR_195942]  (MAP x 
FiO 2) 
• Change in the following measures of hypoxemia (SpO 2<80%): intermittent 
hypoxemia ( events lasting 10s-3min) , prolonged hypoxemia ( events lasting  >1min) , 
and daily proportion of time with hypoxemia 
• Change in tracheal aspi[INVESTIGATOR_195931] , neutrophil /WBC ratio , and patterns in 
the airway microbiome  
• Longitudinal change in dynamic compliance, peak expi[INVESTIGATOR_10229], airway resistance, and carbon dioxide elimination 
 
6.[ADDRESS_232861] descriptive 
statistics  (e.g., means and standard deviations for continuous variables such as age and 
percentages for categorical variables such as gender). 
 
6.3.2 Safety Analysis 
All subjects entered into the phase 1 investigational drug trial of inhaled tobramycin will be 
included in the s afety analysis. The primary study outcome is a safety endpoint and will be 
evaluated as a dichotomous outcome  based on the presence of any of the events listed in 
section 6.1. The 3+3 design flow diagram shown in Figure 8 will be followed to  determine 
enrollment and trial progression based on the results of each infant’s safety analysis.  
In addition, the frequencies of AEs by [CONTACT_24975], body system, severity , and relationship to the 
study drug will be summarized. SAEs (if any) will be described in detail.  
 6.3.3 Exploratory Secondary Safety and Efficacy Analys es 
The exploratory secondary safety and efficacy endpoints listed in section 6.2 will be 
analyzed as described in Table 7 (next page).  In brief, all study data will first be 
summarized using  standard descriptive statistics as appropriate based on data type and 
distribution. Assessments of change over time for all longitudinal  secondary outcome data  
will first be assessed graphically , with and without stratification by [CONTACT_196121] . Next, p aired t-tests or Wilcoxon sign rank tests will be used to compare 
   
   30 
pre-trial baseline values to those recorded at later time points . Non-paired tests will be used 
to compare data baseline and subsequent data points between the infants in the phase 1 
trial and observational (non- treated) cohorts.  
Table 7. Planned statistical techniques and data availability for the phase 1 trial outcomes  
 Values available for:   
Study outcome  Phase 1 
trial cohort  Observational 
cohort  Statistical approach  
Secondary safety  
endpoints  Yes Yes, for some 
endpoints  • Rates of the secondary tolerability endpoints will be summarized 
for each dose level. Descriptive, narrative details of these endpoints will also be provided as appropriate.  
• Data on the rates of endotracheal tube obstruction, unplanned tracheal extubation, and audiology testing results will be compared between the trial and observational cohorts.  
• Planned comparisons of audiology testing results are described in 
the Protection of Human Subjects document.  
Secondary efficacy 
endpoints     
Negative TA culture  
for the target GNR  Yes No • Primary exploratory efficacy endpoint.  
• Rates will be summarized for the trial cohort as a whole and stratified by [CONTACT_196122].   
Change in TA GNR 
pathogen CFU Yes No • Absolute (pre vs post) and relative change ([post trial – pre trial] / 
pre trial) in the target organism CFU/mL on the log [ADDRESS_232862] -trial absolute CFU/mL values for the whole cohort and 
stratified by [CONTACT_196122].  
Tracheal aspi[INVESTIGATOR_196040] • Values, stratified by [CONTACT_196123], will be compared to established 
concentrations necessary to overcome the minimum inhibitory 
concentration needed to kill 90% of detected bacterial isolates 
(MIC 90).90,91 Values will also be used in our PK analyses.  
Tracheal aspi[INVESTIGATOR_196041] • Individual cytokine levels measured pre -trial, ≤48 hours after the 
final dose, and 14 days after the final drug dose will be summarized. Transformation (e.g. logarithmic) or categorization by [CONTACT_196124]. 
Correction for total protein levels in the tracheal aspi[INVESTIGATOR_196042].  
• The relative intra- patient change for the individual cytokine levels 
from pre -trial baseline to the [ADDRESS_232863] -trial timepoints will be 
calculated and compared between dose levels.  
• The association between change in cytokine levels and tobramycin dose will be explored using bivariate and multivariate correlation analyses with Bonferroni correction for multiple testing.
100  
• We will consider exploratory cluster and linear discriminate analyses to identify airway immunological profiles associated with 
differences in the response to inhaled tobramycin (e.g. change in 
CFU/mL).101,102  
Respi[INVESTIGATOR_196043] (SpO 2 
<80%)  Yes Yes • Continuously recorded FiO 2, MAP, and RSS values will be 
converted to time- weighted daily averages for each study day.  
• Continuously recorded SpO 2 data will be used to calculate daily 
rates of intermittent and prolonged hypoxemia and daily total 
hypoxemia exposure.  
• Assessment of longitudinal change using linear mixed effects 
models will be considered.  
Pulmonary 
mechanics  Yes Yes • Infants in both study cohorts will undergo pulmonary mechanics measurements pre- trial, after 7d, and after 14d.  
• Intra-patient change, relative to pre- trial baseline, will be calculated 
for each participant and compared (1) between the two cohorts and (2) stratified by [CONTACT_196123].  
• Assessment of longitudinal change using linear mixed effects 
models will be considered.  
CFU, colony forming units; GNR, Gram -negative rod; TA, tracheal aspi[INVESTIGATOR_337]  
   
   [ADDRESS_232864] strong evidence of a linear change over the course of the study period. These 
models will be considered: (1) for the phase 1 trial participants as a whole, (2) with 
stratification  by [CONTACT_196103], and ( 3) between infants who 
participate in the phase 1 trial and those enrolled in the observational (non-treated) cohort 
(for the study outcome data collected in both cohorts ). Treatment dose group and treatment 
week will be included in the models as independent variables (the latter is added to  account 
for natural f luctuation in disease acuity  over time). Random effects for intercept +/ - slope 
will be considered based on their effect on model fit assessed using the Akaike information criterion . Backwards, stepwise elimination techniques to determine inclusion of poss ible 
confounding, independent covariates will be employed to account for measured differences 
between comparison groups. Adherence to accepted numbers of independent covariates 
based on the study sample size will be used to avoid model over -fitting.
98 If longitudinal 
models are performed, 95% confidence intervals for all estimates of effect will be reported 
and caution will be urged when interpreting these hypothesis generating results.   
 
Patterns in the airway microbiome will be assess ed by [CONTACT_23992] (pre vs. post treatment) 
measures of alpha diversity (e.g. species counts, Shannon index) and beta- diversity 
(Weighted and unweighted UniFrac distances99). Principal coordinate analyses and 
evaluation of dominant taxa will also be used to compare the microbiome before versus 
after completing treatment and with stratification by [CONTACT_196093]. Linear mixed effects models , appropriate for repeated measures data,  will also 
be constructed to measure the association between the dose of inhaled tobramycin and 
measures of alpha diversity.   
 
Lastly, hypothesis generating analyses will assess changes  in bacterial CFU /mL (on the 
log 10 scale) as a function of : (1) the GNR organism cultured from the tracheal aspi[INVESTIGATOR_337], (2) 
pre-trial airway cytokine levels, (3) pre -trial RSS, and (4) pre -trial pulmonary mechanics  
measurements. These data will help inform the selection of pre -specified subgroups group 
analyses that will be performed in future randomized trials.  
 
6.3.4 Pharmacokinetic analysis  
Patient specific pharmacokinetic parameters will be  calculated using log -linear regression 
as the equation: K el = (ln Cp max/Cp min) / t, where K el is the elimination rate constant from 
plasma, Cp max and Cp min and the peak and trough concentrations, respectively , and t is the 
time between samples. Based on this equation, the estimated concentration at the time of 
tracheal aspi[INVESTIGATOR_196044]. The correlation between tracheal and 
plasma tobramycin concentrations will then be determined.  
 Population pharmacokinetic  (PK) analysis will be conducted using nonlinear mixed effects 
modeling with the program NONMEM (Icon Inc.). Dosing information and plasma  
tobramycin concentrations will be used to facilitate model development. Mean population 
PK parameters (clearance, volume of distribution) will be estimated using the first -order 
conditional estimation with interaction method.  A 2-compartment model with fi rst order 
absorption will be utilized based on prior knowledge of inhaled tobramycin.
[ADDRESS_232865] variability and covariate effects (body weight, PMA, renal function, sex ) will be  
   
   32 
assessed. Owing to a lack of existing data on the likely plasma tobramycin levels after 
inhalational administration in the target population, i t is uncertain whether  the sampling 
strategy implemented in this trial will enable formal population PK analysis. Therefore, this 
analysis will be conducted strictly as an exploratory aim.  
 
6.4 Sample Size and Power  
The traditional 3+3 design is  the prevailing method for conducting phase 1 drug trials.103,104 
The sample size for this design is dictated by [CONTACT_196125] a toxic drug response. Up to 24 infants are expected to provide 
analyzable trial data as described in section 3.3.2. The purpose of the 3+3 trial design is to 
continue dose escalation (within set boundaries) until at least two patients among a cohort 
of three to six patients experience dose -limiting toxicities (i.e. , ≥33% of patients with a dose -
limiting toxicity at that dose level).103,104 If the 300mg dose level is completed in 3 
participants  and none show evidence of a toxic response, up to 3 additional infants will be 
enrolled to receive to receive 300mg. The trial will be stopped if 2 of the additional infants receiving 300mg develop a toxic response and the 216mg dose will be used as the 
maximum tolerated dose in subsequent trials.  
 
Enrollment in the observational cohort will run concurrent with  enrollment in the phase 1 
trial. A minimum of 12 infants and a maximum of 28 infants will be enrolled in the observational cohort. This variable enrollment number is selected to avoid delay in study 
closure if enrollment in the trial cohort out paces the observational cohort. Importantly, these numbers are anticipated to provide adequate statistical power to measure clinically 
meaningful differences in the frequency of intermittent hypoxemia, an important measure of 
cardiorespi[INVESTIGATOR_82788] .
96,97 Premature infants with BPD average 75 ( SD ± 9) intermittent 
hypoxemic events (SpO 2 <80% for 10s -3min) per day during the first several months of 
life.105,106 A sample size of 12 infants in the observational cohort and 12 in the trial cohort 
will provide >80% power ( α=0.05) to detect a 15% difference in the mean daily frequency of 
intermittent hypoxemic events between the two groups. A sample size of 24 infants per 
group will provide >80% to detect an 11% difference in i n the mean daily frequency of 
intermittent hypoxemic events.  
 6.5 Interim Analysis  
The 3+3 study design requires analysis of each study participant ’s data in “real time” to 
determine trial progression. After each infant completes the trial, an interim analysi s will be 
performed to determine whether to continue the trial at the present dosage  and enrollment 
number, expand the number of infants enrolled at the present dos age, advance to the next 
dosage, or end the trial after reaching a maximum tolerated dosage ( MTD) or maximum 
planned investigational dosage.  
7 STUDY MEDICATION ( TOBRAMYCIN INHAL ATIONAL SOLUTION, USP ) 
7.[ADDRESS_232866] label for tobramycin inhalational solution, USP (300mg/5mL) is included in 
Appendix  C. As the use of tobramycin in this clinical trial is investigational, the FDA label 
requirements per regulations will be affixed to the investigational product.  
 
7.1.3 Dosing  
This phase 1 , dose escalation trial will investigate up to 4 different dosages of tobram ycin 
solution for inhalation: 78 mg, 150mg , 216mg, and 300mg. Each dose will be administered 
every 12 hours. For administered doses less than 300mg, the investigational pharmacy at 
CHOP will draw- up the appropriate volume from the 300mg/5mL tobramycin inhalational 
solution, USP ampule (i.e. , 78mg = 1.3mL; 150mg = 2.5mL ; 216mg = 3. 6mL) using a single 
3mL syringe (which indicate 0.1mL increments) or 5mL syringe (which indicate 0.2mL 
increments) as appropriate. The measured drug dose will then be  dilute d with sterile normal 
saline to produce a solution for aerosolization totaling 5mL. This will ensure that the same 
volume of liquid is aerosolized at each dosage level. All reconstituted drug product will be 
stored for not more than 4 hours at room  temperature or 24 hours under refrigeration prior 
to administration.  
 7.1.4 Drug delivery via vibrating mesh nebulizer  
Each dose of tobramycin solution for inhalation will be administered using the Aerogen ® 
Nebulizer System (Aerogen solo nebulizing chamber and Pro- X Controller/power source). 
This system utilizes a vibrating mesh nebulizer and is the standard equipment used for the 
delivery of aerosolized medications in the CHOP N/IICU . The Aerogen ® Solo nebulizing 
chamber and Pro- X Controller/power source are suitable for use in infants receiving 
invasive mechanical ventilation and FDA approved for use in children >29 days of age  (see 
FDA approval information and device manual included in Appendix D , E). All study 
participants will b e greater than 29 days of age at study initiation owing to enrollment of 
infants who are  <32 weeks gestational age  and ≥36 weeks PMA  (gestational age + 
chronological age). Th e Aerogen ® Nebulizer System does not contribute additional flow to 
the ventilator circuit.  
 
Vibrating mesh nebulizers employ a central aperture plate that is perforated with precisely 
formed holes. A pi[INVESTIGATOR_196045] a micropump drawing 
liquid thr ough the holes to generate aerosolized particles with a mass median aerodynamic 
diameter (MMAD) of 1 -5µm for a range of different medications.
107-110 Achieving particles of 
this size is essential as smaller particles are more prone to removal during exhalation and 
particles with an MMAD >5 -10µm are susceptible to “rainout” in the nebulizer/ventilator 
circuitry and/or the large, conducting airways.111-113 
 
Bench studies using a pediatric lung model in a mechanically ventilated patient with an 
endotracheal tube (5mm inner diameter) and a tracheostomy tube (4.4mm inner diameter) 
have assessed the proportion of aerosolized drug delivered distal to the breathing tube 
using the Aero gen ® Solo vibrating mesh nebulizer.114,115 The maximum proportion of 
inhaled drug was achieved using a tracheostomy: 19.8% ±  3.0%, likely owing to its shorter 
length despi[INVESTIGATOR_196046].115 Using an endotracheal tube, 13.6% ±  1.3% 
   
   34 
of the drug was delivered when the bias flow was set to 2L/min and 10.6% ±  0.3% when the 
bias flow was set to 5L/min.114 The ventilators used in the CHOP N/IICU  to support infants 
with BPD use a bias flow of either 2.5L/min when set to the pediatric mode (most common 
for the target study population) or 4L/min when set to the neonatal mode. Extrapolating the 
published bench study data114,115 to the mechanical ventilators employed in this  phase 1  
trial, without correction for additional loss owing to the smaller endotracheal tubes use d in 
the study infants (3.5- 4mm), we conservatively estimate that  11-13% of the aerosolized 
drug will reach the respi[INVESTIGATOR_196047]. Further loss of drug 
may occur prior to the alveolar/capi[INVESTIGATOR_196048].116-119 Despi[INVESTIGATOR_196049], the available data indicate the  range of  tobramycin dos ages  under investigation in this 
study will yield a dose that results in sufficient antimicrobial levels to significantly reduc e the 
respi[INVESTIGATOR_196050]. In a study evaluating tobramycin 
levels in the epi[INVESTIGATOR_196051] 30 -45 minutes after 
treatment with 300mg of inhaled tobramycin administered by [CONTACT_196126] 12 young 
children with CF (mean age 3.3 years, range 0.9 to 5 years), the tobramycin concentration 
was within the target range in 11 or 12 patients, with a mean value of 90 µg/mL.26 This level 
is above the minimum inhibitory concentration of 2- 4µg/mL necessary to kill 90% of 
pseudomonas isolates (MIC 90) in vitro  and the necessary sputum levels of approximately 
50µg/mL needed to effectively eradicate P. aeruginosa in the airway.90,[ADDRESS_232867] by [CONTACT_196127] . The study team will also document  each dosage  in separate  study logs. Drug 
administration will be open label.   
 
7.1.6 Drug Accountability  
Adequate records of study drug receipt and disposition will be maintained . The CHOP 
Investigational Drug Service (IDS) Records of receipts, investigational drug orders, 
dispensing records, and disposition forms will be examined during the course of the study. 
The purpose of these records is to ensure regulatory authorities that the investigational new 
drug will not be dist ributed to any person who is not a study subject under the terms and 
conditions set forth in this protocol. The study medication will be  prescribed by [CONTACT_196128].  
 
The CHOP IDS will purchase supplies for the study and partially used and empty containers 
will be discarded at the time of dose preparation to agree with IDS operating procedures.  
 
8 SAFETY MANAGEMENT  
8.1 Clinical Adverse Events 
Clinical adverse events (AE s) will be monitored throughout the study. These will constitute 
both the defined tolerability drug endpoints and additional events that are observed 
clinically or by [CONTACT_76965] (imaging, laboratory analyses) throughout the trial and 
pose a risk to the study participant.  
   
   35 
8.2 Adverse Event Reporting  
The Primary Investigator will hold  responsibility  for recording and reporting unanticipated 
problems related to research that occur during and after study treatment. Unanticipated 
problems related to the research involving risks to subjects or others  that occur during the 
course of this study (including SAEs) will be reported to the IRB in accordance with CHOP 
IRB SOP 408: Unanticipated Problems Involving Risks to Subjects. AEs that are not serious 
but that are notable and could involve risks to subjects will be summarized in narrative or 
other format and submitted to the IRB at the time of continuing review. Adverse event 
reporting will be targeted, so that potential adverse events arising from the use of inhaled tobramycin (for example, inhalational side -effects as well as renal adverse events) will be 
reported, while other adverse effects attributed to the underlying disease or clinical care will 
not be reported. All epi[INVESTIGATOR_48478].  All adverse events 
reported to the CHO P IRB will also be reported in a timely manner to the study DSMB.  
 
8.[ADDRESS_232868] who has received an 
intervention (drug, biologic, or other intervention). The occurrence does not necessarily 
have to have a causal relationship with the treatment. An AE can therefore be any 
unfavorable or unintended sign (including an abnormal laboratory finding, for example)  or 
disease temporally associated with the use of a medicinal product, whether or not it is 
considered related to the medicinal product.  
 All AEs (including serious A Es) will be noted in the study records and on the case report 
form with a full description including the nature, date and time of onset, determination of 
non-serious versus serious, intensity (mild, moderate, severe), duration, causality, and 
outcome of the event.  
 
The likelihood that the adverse event was related to the study drug or a study pr ocedure will 
be classified using the following scheme:  
 
• Unrelated: There is no apparent relationship between the adverse event and a 
study intervention or procedure  
• Unlikely:  It is unlikely that there could be any causal relationship between the 
adverse ev ent and a study intervention or procedure  
• Possibly:  It is a possibility that the adverse event is related to a study intervention 
or procedure  
• Probably:  The adverse event is probably related to a study intervention or 
procedure  
• Definitely:  The adverse event is definitely related to a study intervention or 
procedure  
 
The severity of an adverse event will be classified using the following scheme:  
• Mild: Asymptomatic or mild symptoms; clinical or diagnostic observation only; no 
intervention indicated  
• Moderate: Minimal, local, or non -invasive intervention indicated  
• Severe: Severe or medically significant, but not immediately life threatening; 
prolongation of hospi[INVESTIGATOR_374]/required; disabling.  
• Life- threatening: Life-threatening consequences; urgent intervention indicated  
 
   
   36 
8.4 Definition of a Serious Adverse Event (SAE)  
An SAE is any adverse drug experience occurring at any dose that results in any of the 
following outcomes:  
 
• death,  
• a life -threatening event (at risk of death at the time of the event),  
• prolongation of existing hospi[INVESTIGATOR_196052] a 
preterm infant who requires extended  invasive mechanical ventilation near and 
beyond term corrected gestation, or 
• a persistent or significant disability/incapacity . 
Important medical events that may not result in death, be life- threatening, or require 
hospi[INVESTIGATOR_3767] a serious adverse drug event when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition.  
 Of note, there is a distinction between serious and severe AEs. A severe AE is a major 
event of its type. A severe AE does not necessarily need to be considered serious. For 
example, nausea which persists for several hours may be considered severe nausea, but would not be an SAE. On the other hand, a stroke that results in only a limited degree of 
disability may be considered a mild stroke, but would be an SAE.  
  
8.4.1 Relationship /Severity  of SAE to S tudy D rug or Other I nterventi on 
In accordance with CHOP IRB Guidelines , the relationship of each SAE to the study 
intervention and the severity of the SAE will be characterized as described in section 8.3.  
 
8.5 IRB/IEC Notification of SAEs  and Other Unanticipated Problems  
The Investigator will promptly notify the IRB  and DSMB  of all on- site unanticipated, serious 
Adverse Events that are related to the research activity. Other unanticipated problems 
related to the research involving risk to subjects or others will also be reported promptly.  
 Written reports will be filed using the eIRB system and in accordance with the timeline 
summarized on  page 36. External SAEs that are both unexpected and related to the study 
intervention will be reported promptly after the investigator receives the report.  
 
8.5.1 Follow -up report  
If an SAE has not resolved at the time of the initial report and new information arises that 
changes the investigator’s assessment of the event, a follow -up report including all relevant Type of Unanticipated 
Problem  Initial Notification  
(Phone, Email, Fax)  Written Report  
Internal (on -site) SAEs  
Death or Life Threatening  24 hours  Within 2 calendar days  
Internal (on -site) SAEs  
All other SAEs  7 days  Within 7 business days  
Unanticipated Problems 
Related to Research  7 days  Within 7 business days  
All other AEs  N/A Brief Summary of important 
AEs may be reported at time 
of continuing review  
   
   37 
new or reassessed information (e.g. , concomitant medication, medical history) will be 
submitted to the IRB. The investigator will be  responsible for ensuring that all SAE s are 
followed until either resolved or stable.  
 
8.6 Investigator Reporting of a Serious Adverse Event to Sponsor  
Reporting will be consistent with regulatory  and protocol -specified requirements . 
 8.7 Sponsor Reporting of Serious Adverse Events to FDA  
In the event that a serious adverse event attributed to the investigational drug or its delivery 
occurs, the reporting to the FDA wil l be by [CONTACT_196129].  
 
8.8 Medical Emergencies  
All infants enrolled in the study will be hospi[INVESTIGATOR_196053] N/IICU  throughout the trial . 
All medical emergencies will be handled by [CONTACT_196130]. The study team will be available for consultation if needed.  
 
9 STUDY ADMINISTRATION 
9.1 Treatment Assignment Methods  
Participants in this open label 3+[ADDRESS_232869] (source 
documents). Case report forms will be generated for each subject and maintained in the 
research -focused electronic data capture system REDCap. On occasion, paper case report 
documents may be generated, but will be destroyed as soon as possible after that data has 
been entered into REDCap. See section [ADDRESS_232870] de- identification and 
coding options including removal all identifiers. When we export data for analysis, we will not include any individually identifiable private information.  All study data (including PHI) will 
be maintained for the longer of either  (1) 6 years after publication of the study results  or (2) 
[ADDRESS_232871] marketing approval for the investigational agent (study drug) or, if no 
   
   [ADDRESS_232872] obtaining IRB approval. The investigator will obtain a data use agreement between the provider (the PI) of the data and 
any recipi[INVESTIGATOR_5772] (including others at CHOP ) before sharing a limited dataset.  
 
9.[ADDRESS_232873] (DSMB) will be convened to 
monitor for any safety events associated with this study. At the recommendation of the 
NHLBI safety review committee, the DSMB will consist of 2 neonatologists (1 will serve as  
chair), [ADDRESS_232874] confidentiality will 
be carried out as described in section 9. Adverse events wil l be monitored for and reported 
as described in section 8. 
 
[IP_ADDRESS] Responsibilities of the DSMB  
The DSMB is responsible for safeguarding the interests of study participants, assessing the safety and efficacy of study procedures, and for monitoring the overall con duct of the study.  
The DSMB will regularly review study safety data. As this is an open- label phase 1 dose 
escalation trial, all study data will be provided to the DSMB without masking of administered 
drug dose levels.  
 The DSMB is an independent group advisory to the investigators and affiliated institution, 
and is required to provide recommendations about starting, continuing, and stoppi[INVESTIGATOR_90348]. The DSMB makes recommendations about:  
• Participant safety and risk/benefit ratio of study procedures and i nterventions, 
including whether new data from other sources affects the study  
• Initial approval of the protocol and subsequent amendments (with specific attention 
to study population, intervention, and study procedures)  
• Initial approval of consent forms and  subsequent amendments  
• Study burden on participants  
• Recruitment, and retention of participants  
• Completeness, quality, and planned analysis of data  
• Performance of individual centers and core labs  
• Review of plans for incidental findings  
• Ancillary study bur den on participants and main study  
 
[IP_ADDRESS] Communication plan  
The diagram shown below illustrates the flow of information between the DSMB and other entities in this study.   
 
   
   [ADDRESS_232875] the DSMB when needed for urgent 
concerns or clarifications of recommendations.  
 
[IP_ADDRESS] Scheduling, timing, and organization of DSMB meetings 
The purpose of the first meeting is to review and discuss this charter, provide an overview 
of study activities, review and make recommendations about the protocol(s), informed 
consent materials, determine the frequency of interim analyses, finalize the DSMB data 
reporting template, and decide whether data will be unmasked to randomized group. 
Enrollment in a study cannot begin until the DSMB’s and IRB’s recommendations for 
approval.  
 
• Meetings (in person or by [CONTACT_577]) will be held 2 times a year , with 
additional meetings scheduled as needed.  
 
• Summaries of interim data analyses will be provided to the DSMB chair prior to each drug dose escalation. The DSMB chair may choose to convene a full DSMB 
meeting to discuss these findings and place the study on temporary hold as needed.  
  
• The DSMB will conclude its operations when all study procedures and planned 
primary data analyses are completed.  
 
The agenda for DSMB meetings and calls may be drafted by [CONTACT_978] [INVESTIGATOR_196054], and finalized after consultation with the DSMB Chair. The agenda and 
meeting materials will be distributed by [ADDRESS_232876] limits the ability of the DSMB member to participate in the 
discussion; according to the conflict of interest policy at the grantee institution.  
 
The DSMB will review the following data: adverse events and other safety data, quality and 
completeness of study data, quality report(s) of any core(s), and enrollment  data at each 
meeting to ensure proper trial conduct. The DSMB may also review formal interim analyses of drug tolerability endpoints prior to each planned drug dose escalation.  
The expertise of the attending members should be appropriate for the agenda of the meeting. It’s expected that all DSMB members will  attend every meeting. The Chair may 
designate replacements for a meeting. For the purposes of voting on recommendations, a 
quorum is [ADDRESS_232877] may also decide in 
advance whether ad hoc  members can vote.  
 Meetings are organized into open, closed, and executive sessions.  
 
• Open session - information is presented to the DSMB by [CONTACT_30967], 
with time for discussion.   
 
• Closed session  - the DSMB, select study staff, and NHLBI program staff (at the 
Chair’s discretion) discuss confidential data (any study data grouped by [CONTACT_54012]), including information on drug dose safety.  
 The principal investigator [INVESTIGATOR_196055].   
 
• Executive session  (optional) -- DSMB members, and NHLBI program staff (at the 
Chair’s discretion), may convene to discuss study issues independently.  
 
• Recommendations (optional) – Meet ing attendees may be reconvened to receive 
the DSMB’s recommendations.  
 
If the executive session occurs on a conference call, steps will be taken to ensure that only 
the appropriate participants are on the call, and to invite others to re -join the call onl y at the 
conclusion of the executive session.  
 
[IP_ADDRESS] Reports to the DSMB  
For each meeting, the study biostatistician will prepare summary reports and tables to 
facilitate the oversight role of the DSMB. The DSMB will discuss at the first or subsequent 
meetings w hat data they wish to review and how it should be presented.  
 
[IP_ADDRESS] Statistical monitoring guidelines  
At the first meeting, review of the protocol will include review of the statistical analysis plan. 
The DSMB will discuss the adequacy of that plan.  The DSMB will discuss the statistical 
monitoring procedures they propose to follow to guide their recommendations about 
termination or continuation of the trial. These procedures could include guidelines for early 
termination for safety reasons.  
 
[IP_ADDRESS] DSMB recommendation s 
Voting on recommendations will follow Roberts’ Rules of Order ( Robert's Rules of Order 
Newly Revised (11th Edition) RONR.  
 
Board Recommendations signed by [CONTACT_45453], will be sent to the investigators within 7 calendar days after the meeting. Recommendations should include a statement as to 
whether the study, is approved to continue as planned, should continue with specified 
changes, or should be stopped. Requests for additional data from the investigators or study 
statistician should include an expec ted due date. In addition to recommendations memos 
issued to investigators (for review and IRB distribution), recommendations related to data 
analysis issues may be issued separately for statisticians.  
 
   
   41 
Recommendations are distributed by [CONTACT_458] [INVESTIGATOR_196056].  
 
[IP_ADDRESS] Additional monitoring  
Before the initiation of the clinical investigation, the sponsor ‐investigator will arrange a 
pretrial monitoring visit with the Office of Research Compliance (ORC) to confirm clinical 
trial readiness. After enrolling and starting administration of the investigational agent to the first subject, the sponsor ‐investigator will contact [CONTACT_196131] a monitoring visit. 
Thereafter, ORC will monitor the study at least annually. Moni toring activities will be guided 
by [CONTACT_12212] E6 section 5.18. Interim monitoring activities will include 100% review of regulatory 
files as well as a percentage of enrolled subject records, source documents, applicable 
informed consent forms, and case report fo rms. The percentage of subject data review may 
be amended throughout the course of the study based on an ongoing risk assessment. A 
tapered approach to monitoring may be employed, if conduct and documentation of the 
study reaches a level of reliability tha t would permit valid conclusions based upon a 
sampling of data.  
 
9.4.[ADDRESS_232878] of 2µg/mL, or any evidence of significant, new onset 
end-organ injury as measured by [CONTACT_196132] . 
 
Blood draws for research purposes may also pose a risk to the study participants. Infants 
with BPD receiving care in the CHOP N/IICU  typi[INVESTIGATOR_196057]. Study team members will make every effort to coordinate with the medical t eam such 
that study blood collections might occur  concurrent with other clinically indicated blood 
draws . All blood draws will be performed by [CONTACT_196133], either via hee l stick, venipuncture, or indwelling catheter. Phlebotomy may 
cause some pain, bleeding, or bruising. Rarely, taking blood may cause infection.  To 
ensure collection of the necessary volume of blood for this research ( up to 1.7mL per draw) 
does not incur risk to the patient, study team members, in  consultation with nursing staff, 
will ensure that volume of blood extraction (for clinical + research purposes) does not 
exceed the maximum allowable weight -based limits specified by [CONTACT_196134] 
(no more than 5 mL/kg drawn in a single day). I n the event that excess blood draw is 
possible, the research team will coordinate with the medical team to prioritize laboratory 
testing to ensure patient safety.  
 
Suctioning of the endotracheal tube is not anticipated to incur additional risk to the study 
participants as this is a routine clinical procedure for infants receiving invasive mechanical ventilation in the CHOP N/ IICU. Infants receiving invasive mechanical ventilation undergo 
ET tube suctioning as part of routine clinical care several times  throughout the day. 
Whenever possible, study staff will coordinate with nursing and respi[INVESTIGATOR_196058]. ET suctioning 
   
   42 
involves interruption of mechanical ventilation for ≤5 seconds , equivalent to the interval 
between 1- 2 breaths for many infants.  
 
Placement of the in- line sensor for the Philips Respi[INVESTIGATOR_195981]3 respi[INVESTIGATOR_196059] ( ≤5 seconds) interruption of mechanical ventilation. Mechanical 
ventilation is briefly interrupted in infants with BPD on a daily basis as part of routine clinical 
care for reasons such as suctioning of the endotracheal tube, repositioning of the infant, 
and replacement or maintenance of the ventilator equipment. These brief interruptions  are 
well tolerated in most infants.  
 
Pulse oximetry is part of routine clinical care. For this study, an additional research monitor 
will be used. The adhesive used can on rare occasions  result in  minor skin irritation.   
 
The other risk to participat ion in this study is breach of subject confidentiality. The study will 
employ extensive data security measures (see sections 9.2  and 9.3) to protect participant 
privacy.  
 
9.4.3 Potential Benefits of Trial Participation  
Colonization/infection of the lungs  with pathogenic GNR organisms  in preterm infants with 
BPD, and in multiple other pediatric and adult respi[INVESTIGATOR_14437] , is associated with 
respi[INVESTIGATOR_196060] .10,11,16,[ADDRESS_232879] 
colonization with P. aeruginosa (the most common GNR detected in the airways of infants 
receiving invasive mechanical ventilation for BPD).10,16,[ADDRESS_232880] to mitigate the study risks, the potential benefits of 
treatment with inhaled tobramycin outweigh the risks associated with participation in this 
trial. Participation in the observational cohort is expected to be minimal risk. 
 
9.5 Recruitment Strategy  
All subjects will be recruited from the CHOP N/IICU . Unit census documents will be 
reviewed weekly to identify possible subjects. For subjects likely to be eligible, medical 
records will be further reviewed to assess eligibility (only the number of subjects screened 
for eligibility and no specific subject level data will be recorded prior to informed consent). 
The Investigator or a designated study team member will confirm eligibility with the potential 
subject’s attending physician and request permission to approach the parent(s) or 
guardian(s). If appropr iate, the parent(s) or guardian(s) of eligible subjects will be 
approached and details of the study will be discussed. If interested, the parent(s) or 
guardian(s) will be invited to participate. Study personnel will then review the information in 
the consent form, answer any questions, and obtain informed consent. A study team 
physician will obtain consent for participation in the phase [ADDRESS_232881] preterm infants with BPD who require prolonged invasive mechanical ventilation are 
followed by [CONTACT_196135] (NeoCLD) Program. The NeoCLD program is comprised of physicians, respi[INVESTIGATOR_46175], and nurses who are 
jointly engaged in clinical care and research. Every year 60- 70 infants are admitted to 
CHOP and cared for by [CONTACT_196136]. Another 15- 20 admitted to the CHOP N/IICU  
require prolonged mechanical ventilation but do not receive care from the NeoCLD 
program. Together, these admission rates indicate up to [ADDRESS_232882] 2 years, over 60% 
of eligible infants were enrolled and retained in clinical trials conducted in the CHOP N/IICU. Based  on this rate, we estimate that 30 -50 infants will undergo a screening tracheal 
aspi[INVESTIGATOR_196061]. Our prior data show that 54- 60% of infants 
in the BPD population at CHOP have tracheal aspi[INVESTIGATOR_196062] . Accordingly, we expect to enroll 15 -30 infants per year into the phase 1 trial 
or observational cohort. Based on these numbers  we anticipate this study  will require up to 
3 years to complete . If all enrolled infants successfully complete the 14 -day phase 1 trial, 
we anticipate the study will require up to 18 months to complete.  
 
9.6 Informed Consent/Assent and HIPAA Authorization  
After determining eligibility and obtaining permission from the attending physician, a study 
team member will contact a potential participant’s parent (s) or guardian(s) to obtain 
informed consent and HIPAA authorization. This study will obtain informed consent in [ADDRESS_232883] a screening tracheal aspi[INVESTIGATOR_196063] 1 trial of inhaled tobramycin or the untreated 
observational cohort. Second, for infants whose tracheal aspi[INVESTIGATOR_195967] a 
pathogenic GNR organism, consent will be obtained to enroll in either the phase 1 trial or 
observational cohort.  
 During t he initial consent conversation(s) , the study team will provide a description of the 
goals and study procedures involved in  the phase [ADDRESS_232884]  a research tracheal aspi[INVESTIGATOR_196064] . Consent to participate in the phase 1 trial or observational cohort  will not be 
obtained until after the results of the tracheal aspi[INVESTIGATOR_196065].  Our initial 
consent discussions will be conducted in the N/ IICU in a private setting or via the 
telephone.  Before collection of a screening tracheal aspi[INVESTIGATOR_196066]/PHI, the 
screening consent form must be signed by a legally acceptable surrogate and the 
investigator -designated research professional obtaining the consent if consent is obtained 
in per son. If consent  for screening procedures  is obtained via the telephone, the consent 
form will be signed by [CONTACT_093] -designated research professional obtaining the 
consent and a study team member or clinician witnessing and verifying consent. Parent s or 
guardians providing consent via telephone will be provided a copy of the consent form 
(either via email or left at the baby’s bedside as per their preference).  
For those infants whose screening tracheal aspi[INVESTIGATOR_195967] a pathogenic GNR, a second consent discussion will take place to cover the goals, procedures, risks, 
and benefits of the phase [ADDRESS_232885] in in a private setting in the N/IICU or via tele phone. Enrollment 
   
   44 
in either study cohort will be offered but an infant may only be enrolled in one of the study 
cohorts (phase 1 trial or observational cohort).  Consent for the observational cohort will be 
obtained either in person or via telephone, throug h a waiver of documentation of consent.   
 
Before any study procedures take place, all necessary  consent form s must be signed by a 
legally acceptable surrogate and the investigator -designated research professional 
obtaining the consent.  
 
Consent to participate in the phase 1 drug trial will be obtained by a physician member of 
the study team. Consent for the phase 1 drug trial will be obtained either through written 
consent or through electronic consent (also known as eConsent) . Electronic  consent will 
utilize the  REDCap survey method.  The 21 Code of Federal Regulations (CFR) Part [ADDRESS_232886] confidentiality. REDCap’s 
eConsent automatically returns a signed copy to the parent if he/she agrees to participate.   
 
Parents/guardians with limited English proficiency will consent using the short form process. 
Short forms in the preferred language will be obtained from the CHOP IRB website. The Study Summary document  will be signed by [CONTACT_196137]/interpreter. The short form document will be signed by [CONTACT_7071]/guardian and 
the witness/interpreter. Consent will only occur in person with the study team, 
parent/guardian, and i nterpreter all present.  
 
Whenever feasible, consent conversations will take place in person. At the conclusion of all 
consent discussions, parent(s) or guardian(s) will be provided the opportunity to ask 
questions about the study and to discuss the study with their family, friends, and/or other 
medical professionals. As there are no negative repercussions for lack of participation,  we 
do not anticipate a significant risk of coercion or undue influence to participate.  
 
9.6.1 Waiver of Assent  
A waiver of assent is requested as all study participants are infants and  incapable of 
providing assent  under any circumstances.  
 
9.7 Payment to Subjects/Families  
Subjects and/or families will not receive financial compensation for participation in this 
study . 
 
10 PUBLICATION  
Following completion of this study, results and analyses will be presented at research 
meetings and published in in scholarly journals.  
  
   
   45 
11 REFERENCES  
1. Selewski DT, Charlton JR, Jetton JG, et al. Neonatal Acute Kidney Injury. 
Pediatrics. 2015;136(2):e463- 473. 
2. Selewski DT, Cornell TT, Heung M, et al. Validation of the KDIGO acute kidney 
injury criteria in a pediatric critical care population. Intensive Care Med. 
2014;40(10):1481 -1488.  
3. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., 
Suppl. 2012; 2: 1– 138. 
4. Jensen EA, Schmidt B. Epi[INVESTIGATOR_196067]. Birth Defects Res A Clin Mol Teratol. 2014;100(3):145 -157. 
5. Fawke J, Lum S, Kirkby J, et al. Lung function and respi[INVESTIGATOR_196068] 11 years 
in children born extremely preterm: the EPI[INVESTIGATOR_66554]. Am J Respir Crit Care Med. 
2010;15(182):237 -245. 
6. Murray CJL, Atkinson C, Bhalla K, et al. The state of US health, 1990 -2010: burden 
of diseases, injuries, and risk factors. JAMA. 2013;310(6):591 -608. 
7. Murray C, Lopez A. Measuring the global burden of disease. N Engl J Med. 
2013;369(5):448 -457. 
8. Jensen E, Dysart K, Gantz M, et al. The diagnosis of bronchopulmonary dysplasia in 
very preterm infants: an evidence- based approach. Am J Respir Crit Care Med. 
2019;200(6):751 -759. 
9. Zhang H, Dysart K, Kendrick D, et al. Prolonged respi[INVESTIGATOR_196069]. Pediatr Pulmonol. 2018; 53(10):1447 -55. 
10. Tramper J, Zhang H, Foglia EE, et al. The Association between Positive Tracheal Aspi[INVESTIGATOR_196070]. Am J Perinatol. 2017;34(1):[ADDRESS_232887] colonization with gram -negative 
bacilli: association with severity of bronchopulmonary dysplasia. Pediatr Infect Dis J. 
1997;16(1):18 -23. 
12. Lowe J, Watkins WJ, Edwards MO, et al. Association between pulmonary 
ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: 
updated systematic review and meta -analysis. Pediatr Infect Dis J. 2014;33(7):697-
702. 
13. Rodvold K, George J, Yoo L. Penetration of anti -infective agents into pulmonary 
epi[INVESTIGATOR_71444]: focus on antibacterial agents. Clin Pharmacokinet. 
2011;50(10):[ADDRESS_232888] JP. Hypoxic pulmonary 
vasoconstriction. Physiol Rev. 2012;92(1):367- 520. 
15. Smith S, Rowbotham NJ, Regan KH. Inhaled anti -pseudomonal antibiotics for  long-
term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2018;3:CD001021.  
16. Mogayzel PJ, Naureckas E, Robinson K, et al. Cystic Fibrosis Foundation 
pulmonary guideline. pharmacologic approaches to prevention and eradication of 
initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11(10):1640 -
1650.  
17. Le J, Ashley E, Neuhauser M, et al. Consensus summary of aerosolized 
antimicrobial agents: application of guideline criteria. Insights from the Society of 
Infectious Diseases Pharmacist s. Pharmacotherapy. 2010;30(6):[ADDRESS_232889], Scardina T, Danziger LH. Inhaled antibiotics for Gram -
negative respi[INVESTIGATOR_18073]. Clin Microbiol Rev. 2016;29(3):581 -632. 
   
   46 
19. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal 
ciprofloxacin in non -cystic fibrosis bronchiectasis (ORBIT -2): a randomised, double-
blind, placebo- controlled trial. Thorax. 2013;68(9):812- 817. 
20. Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator -
associat ed tracheobronchitis in the intensive care unit. Crit Care Med. 
2008;36(7):2008 -2013.  
21. Wang X, Koehne- Voss S, Anumolu SS, Yu J. Population Pharmacokinetics of 
Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis. J Pharm 
Sci. 2017;106(11):3402- 3409.  
22. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr 
Pulmonol. 2007;42(4):307- 313. 
23. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of 
tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst 
Fibros. 2011;10(1):54- 61. 
24. Ratjen F, Moeller A, McKinney ML, et al. Eradication of early P. aer uginosa infection 
in children <7years of age with cystic fibrosis: The early study. J Cyst Fibros. 
2019;18(1):78 -85. 
25. Ratjen F, Munck A, Kho P, Angyalosi G, ELITE Study Group . Treatment of early 
Pseudomonas aeruginosa infection in patients with cystic f ibrosis: the ELITE trial. 
Thorax. 2010;65(4):286- 291. 
26. Rosenfeld M, Gibson R, McNamara S, et al. Serum and lower respi[INVESTIGATOR_196071]. J Pediatr. 2001;139(4):572 -577. 
27. Doring G, Flume P, Heijerman H, Elborn JS, Consensus Study G roup. Treatment of 
lung infection in patients with cystic fibrosis: current and future strategies. J Cyst 
Fibros. 2012;11(6):461- 479. 
28. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas 
aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 
2017;4:CD004197.  
29. Tadrous M, Khuu W, Paterson J, Mamdani M, Juurlink D, Gomes T. Off -label use of 
inhaled tobramycin in Ontario, Canada. Thorax. 2016;71(9):862 -864. 
30. Migiyama Y, Hirosako S, Tokunaga K, et al. Aerosolized tobramycin for 
Pseudomonas aeruginosa ventilator -associated pneumonia in patients with acute 
respi[INVESTIGATOR_1505]. Pulm Pharmac ol Ther. 2017;45:142- 147. 
31. Hallal A, Cohn S, Namias N, et al. Aerosolized tobramycin in the treatment of 
ventilator -associated pneumonia: a pi[INVESTIGATOR_799]. Surg Infect (Larchmt). 2007;8(1):73 -
82. 
32. Ramsey B, Pepe M, Quan J, et al. Intermittent administra tion of inhaled tobramycin 
in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N 
Engl J Med. 1999;340(1):23- 30. 
33. Murphy T, Anbar R, Lester L, et al. Treatment with tobramycin solution for inhalation 
reduces hospi[INVESTIGATOR_196072]. Pediatr 
Pulmonol. 2004;38(4):314- 320. 
34. MacLusky I, Gold R, Corey M, Levison H. Long- term effects of inhaled tobramycin in 
patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr 
Pulmonol . 1989;7(1):42- 48. 
35. Smith A, Ramsey B, Hedges D, et al. Safety of aerosol tobramycin administration for 
3 months to patients with cystic fibrosis. Pediatr Pulmonol. 1989;7(4):265 -271. 
36. Ramsey B, Dorkin H, Eisenberg J, et al. Efficacy of aerosolized t obramycin in 
patients with cystic fibrosis. N Engl J Med. 1993;328(24):1740- 1746.  
   
   [ADDRESS_232890]. 
2005;127(4):1420 -1426.  
38. Drobnic M, Suñé P, Montoro J, Ferrer A, Orriols R. Inhaled tobramycin in non- cystic 
fibrosis patients with bronchiectasis and chronic bronchial infection with 
Pseudomonas aeruginosa. Ann Pharmacother. 2005;39(1):39 -44. 
39. Barker A, Couch L, Fiel S, et al. Tobramycin solution for inhalation reduces sputum 
Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 
2000;162(2 Pt 1):481- 485. 
40. By[CONTACT_196138], Vidmar S, Cheney JL, et al. Prospective evaluation of respi[INVESTIGATOR_22315] i n children with cystic fibrosis from newborn screening to 5 years of 
age. Thorax. 2013;68(7):643- 651. 
41. Wainwright C, Vidmar S, Armstrong D, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in 
children with cystic fibrosis: a randomized trial. JAMA. 2011;306(2):163- 171. 
42. Gibson R, Emerson J, McNamara S, et al. Significant microbiological effect of 
inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 
2003;167(6):841 -849. 
43. Treggiari M, Retsch -Bogart G, Mayer -Hamblett N, et al. Comparative efficacy and 
safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in 
children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165(9) :847- 856. 
44. Taccetti G, Bianchini E, Cariani L, et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax. 2012;67(10):853 -859. 
45. Wiesemann H, Steinkamp G, Ratjen F, et al. Placebo- controlled, double- blind, 
randomized study of aerosolized tobramycin for early treatment of Pseudomonas 
aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol. 1998;25(2):[ADDRESS_232891] Fibros. 2013;12(1):29- 34. 
47. Choi J, Novak K, Thompson R. Evaluation of inhaled tobramycin in early eradication 
of Pseudomonas aeruginosa in infants with cystic fibrosis. Pediatr Pulmonol. 
2018;53(S2):275 (Abstract No. 338).  
48. Miller JL, Lepa TM, Ranallo C, Chaaban H, Skrepnek GH, Johnson PN. Detectable 
Concentrations of Inhal ed Tobramycin in Critically Ill Children Without Cystic 
Fibrosis: Should Routine Monitoring Be Recommended? Pediatr Crit Care Med. 2017;18(12):e615 -e620.  
49. Abdulhamid I, Wise T, Andrews S, Biglin K, Lehr V. Elevated serum tobramycin 
concentrations after treatment with tobramycin inhalation in a preterm infant. 
Pharmacotherapy. 2008;28(7):939- 944. 
50. Howard -Thompson A, Christensen M. Elevated tobramycin concentrations following 
endotracheal administration in a premature infant. J Pediatr Pharmacol Ther. 
2008;13(2):88 -92. 
51. Chambers HF. Aminoglycosides. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed, Hardman JG, Limbird LE, Molinoff PB, et al. (Eds), 
McGraw -Hill, [LOCATION_001] 2006.  
52. McWilliam SJ, Antoine DJ, Smyth RL, Pi[INVESTIGATOR_47027] M. Aminoglycoside- induced 
nephrotoxicity in children. Pediatr Nephrol. 2017;32(11):2015- 2025.  
53. Hoffmann I, Rubin B, Iskandar S, Schechter M, Nagaraj S, Bitzan M. Acute renal 
failure in cystic fibrosis: asso ciation with inhaled tobramycin therapy. Pediatr 
Pulmonol. 2002;34(5):375- 377. 
   
   48 
54. FDA approved drug label for tobramycin inhalation solution, USP. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050753s016lbl.pdf  
Accessed May 17, 2019. .  
55. Hennig S, McKay K, Vidmar S, et al. Safety of inhaled (Tobi(R)) and intravenous 
tobramycin in young children with cystic fibrosis. J Cyst Fibros. 2014;13(4):428 -434. 
56. Vella -Brincat JW, Begg EJ, Robertshawe BJ, Lynn AM, Borrie TL, Darlow BA. Are 
gentamicin and/or vancomycin associated with ototoxicity in the neonate? A retrospective audit. Neonatology. 2011;100(2):186 -193. 
57. Puia-Dumitrescu M, Bretzius OM, Brown N, et al. Evaluation of gentamicin exposure 
in the neonatal intensive care unit and hearing function at discharge. J Pediatr. 
2018;203:131 -136. 
58. Vohr B. Infants and children with hearing loss --part 2: overview. Ment Retard Dev 
Disabil Res Rev. 2003;9(4):218 -219. 
59. Robertson C, Tyebkhan J, Peliowski A, Etches P, Cheung P. Ototoxic drugs and 
sensorineural hearing loss following severe neonatal respi[INVESTIGATOR_1399]. Acta 
Paediatr. 2006;95(2):214 -223. 
60. Ding Y, Leng J, Fan F, Xia B, Xu P. The role of mitochondrial DNA mutations in hearing loss. Biochem Genet. 2013;51(7- 8):588 -602. 
61. Guan M. Mitochondrial 12S rRNA mutations associated with aminoglycoside 
ototoxicity. Mitochondrion. 2011;11(2):237 -245. 
62. Göpel W, Berkowski S, Preuss M, et al. Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants. 
BMC Pediatr. 2014;14:210.  
63. Ariano R, Zelenitsky S, Kassum D. Aminoglycoside- induced vestibular injury: 
maintaining a sense of balance. Ann Pharmacother. 2008;42(9):1282- 1289.  
64. Edson R, Brey R, McDonald T, Terrell C, McCarthy J, Thibert J. Vestibular toxicity 
due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc. 
2004;79(9):1185 -1191.  
65. Ahya V, Doyle A, Mendez J, et al. Renal and vestibular toxicity due to inhaled 
tobramycin in a lung transplant recipi[INVESTIGATOR_841]. J Heart Lung Transplant. 2005;24(7):932-
935. 
66. Kaufman A, Eliades S. Vestibulotoxicity in a patient without renal failure after 
inhaled tobramycin. Am J Otolaryngol. 2019;Mar 19 [Epub ahead of print]. 
67. Clavel A, Boulamery A, Bosdure E, et al. Nebulisers comparison with inhaled 
tobramycin in young children with cystic fibrosis. J Cyst Fibros. 2007;6(2):137-1 43. 
68. Plioplys A, Kasnicka I. Nebulized tobramycin: prevention of pneumonias in patients with severe cerebral palsy. J Pediatr Rehabil Med. 2011;4(2):155 -158. 
69. Varricchio A, Tricarico D, De Lucia A, et al. Inhaled tobramycin in children with acute 
bacterial rhinopharyngitis. Int J Immunopathol Pharmacol. 2006;19(1):131 -140. 
70. Vandenbussche H, Homnick D. Evaluation of serum concentrations achieved with an empi[INVESTIGATOR_196073]- daily tobramycin dosage regimen in children and adults with cystic 
fibrosis. J Pediatr Pharmacol Ther. 2012;17(1):67 -77. 
71. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early 
Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138(5):699 -
704. 
72. Proesmans M, Balinska- Miskiewicz W, Dupont L, et al. Evaluating the "Leeds 
criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir 
J. 2006;27(5):[ADDRESS_232892] of histological chorioamnionitis on tracheal aspi[INVESTIGATOR_196074]. Am J Perinatol. 2012;29(7):567 -
572. 
   
   49 
74. Aghai ZH, Saslow JG, Mody K, et al. IFN -gamma and IP -10 in tracheal aspi[INVESTIGATOR_196075]: relationship with bronchopulmonary dysplasia. Pediatr 
Pulmonol. 2013;48(1):8- 13. 
75. Schneibel KR, Fitzpatrick AM, Pi[INVESTIGATOR_196076], Brown LA, Gauthier TW. Inflammatory mediator patterns in tracheal aspi[INVESTIGATOR_196077]. J Perinatol. 2013;33(5):383 -387. 
76. Darlow B, Sluis K, Inder T, Winterbourn C. Endotracheal suctioning of the neonate: 
comparison of two methods as a source of mucus material for research. Pediatr 
Pulmonol. 1997;23(3):217- 221. 
77. Finn D, De Meulemeester J, Dann L, et al. Respi[INVESTIGATOR_196078]. Arch Dis Child Fetal Neonatal Ed. 2018;103(5):F417 -F421.  
78. Murthy V, D'Costa W, Nicolaides K, et al. Neuromuscular blockade and lung function during resuscitation of infants with congenital diaphragmatic hernia. 
Neonatology. 2013;103(2):[ADDRESS_232893], Norberg M, et al. Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide. Pediatrics. 
2007;119(4):670 -678. 
80. FDA approved label for tobramycin injection, USP. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/065122s008lbl.pdf
 
Accessed May 17, 2019. .  
81. Pedersen S, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute 
toxicity of repeated high- dose tobramycin treatment in cystic fibrosis. Antimicrob 
Agents Chemother. 1987;31(4):594 -599. 
82. Mazurek H, Chiron R, Kucerova T, et al. Long -term efficacy and safety of 
aerosolized tobramycin 300 mg/4 ml in cystic fibrosis. Pediatr Pulmonol. 
2014;49(11):1076 -1089.  
83. Gray P, Sarkar S, Young J, Rogers Y. Conductive hearing loss in preterm infants 
with bronchopulmonary dysplasia. J Paediatr Child Health. 2001;37(3):278- 282. 
84. Suppi[INVESTIGATOR_196079] A, Rizzardi E, Zanardo V, Franzoi M, Ermani M, Orzan E. Reliability of hearing screening in high- risk neonates: comparative study of otoacoustic emission, 
automated and conventional auditory brainstem response. Clin Neurophysiol. 2007;118(4):869 -876. 
85. Garinis A, Kemph A, Tharpe A, Weitkamp J, McEvoy C, Steyger P. Monitoring 
neonates for ototoxicity. Int J Audiol. 2018;57(sup4):S41- S48. 
86. Year 2019 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs. Journal of Early Hearing Detection and 
Intervention. 2019;4(2),1 -44. 
87. Zhou X, Cipriano E, Nilan K, Stoller J, Zhang H. Failed hearing screening in infants 
with severe bronchopulmonary dysplasia and associated risk factors [Abstract]. 
Eastern Sociaty of Pediatric Reserach Annual Meeting. 2017;Philadelphia, PA.  
88. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of 
pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23(5):330- 335. 
89. Mayer -Hamblett N, Kronmal RA, Gibson RL, et al. Initial Pseudomonas aeruginosa 
treatment failure is associated with exacerbations in cystic fibrosis. Pediatr 
Pulmonol. 2012;47(2):125- 134. 
90. Rosenfeld M, Gibson R, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 
2001;32(5):356 -366. 
   
   50 
91. Shteinberg M, Elborn J. Use of inhaled tobramycin in cystic fibrosis. Adv Ther. 
2015;32(1):1 -9. 
92. Iyer NP, Mhanna MJ. Non- invasively derived respi[INVESTIGATOR_196080]. Pediatr Pulmonol. 2013;48(4):364-
369. 
93. Malkar MB, Gardner  WP, Mandy GT, et al. Respi[INVESTIGATOR_196081] 
30 is predictive of mortality and the length of mechanical ventilation in premature 
infants with protracted ventilation. Pediatr Pulmonol. 2015;50(4):363- 369. 
94. Jung YH, Jang J, Kim HS, et al. Respi[INVESTIGATOR_196082] a predictive factor for 
severe bronchopulmonary dysplasia or death in extremely preterm infants. BMC 
Pediatr. 2019;19(1):121.  
95. Szakmar E, Morley CJ, Belteki G. Leak Compensation During Volume Guarantee 
With the Drager Baby[CONTACT_196139]500 Neonatal Ventilator. Pediatr Crit Care Med. 
2018;19(9):861 -868. 
96. Jensen E, Zhang H, Feng R, et al. Individualising care in severe bronchopulmonary 
dysplasia: a series of N -of-1 trials comparing transpyloric and gastric feeding. Arch 
Dis Child Fetal Neonatal Ed. 2019;Nov 4 [Epub ahead of print].  
97. Poets CF, Roberts RS, Schmidt B, et al. Association between intermittent 
hypoxemia or bradycardia and late death or disability in extremely preterm infants. 
JAMA. 2015;314(6):595- 603. 
98. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epi[INVESTIGATOR_5541]. 2007;165(6):710- 718. 
99. Lozupone C, Hamady M, Kni ght R. UniFrac -  An online tool for comparing microbial 
community diversity in a phylogenetic context. BMC Bioinformatics. 2006;7:371.  
100. Genser B, Cooper PJ, Yazdanbakhsh M, Barreto ML, Rodrigues LC. A guide to 
modern statistical analysis of immunologic al data. BMC Immunol. 2007;8:27.  
101. Everitt B, Landau S, Leese M, Stahl D. Front Matter, in Cluster Analysis, 5th Edition.  
Chichester, [LOCATION_006]: John Wiley & Sons, Ltd; 2011.  
102. Huberty C, Olejnik S. Frontmatter, in Applied MANOVA and Discriminant Analysis, 
2nd Edition.  Hoboken, NJ, [LOCATION_003]: John Wiley & Sons, Inc.; 2006.  
103. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical 
trials. J Natl Cancer Inst. 2009;101(10):708- 720. 
104. Storer B. Design and analysis of phase I clinical tr ials. Biometrics. 1989;45(3):925-
937. 
105. DiFiore JM, Bloom JN, Orge F, et al. A Higher Incidence of Intermittent Hypoxemic 
Epi[INVESTIGATOR_196083]. Journal of 
Pediatrics. 2010;157(1):69- 73. 
106. Martin RJ, Wang K, Köroğlu Ö, Di Fiore J, Kc P. Intermittent hypoxic epi[INVESTIGATOR_138055]: Do they matter? Neonatology. 2011;100(3):303 -310. 
107. Bohr A, Beck -Broichsitter M. Generation of tailored aerosols for inhalative drug 
delivery employing recent vibrating- mesh nebulizer systems. Ther Deliv. 
2015;6(5):621 -636. 
108. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to 
generate aerosol. Respir Care. 2002;47(12):1406 -1416.  
109. Sidler -Moix A, Di Paolo E, Dolci U, Berger -Gryllaki M, Cotting J, Pannatier A. 
Physicochemical aspects and efficiency of albuterol nebulization: comparison of 
three aerosol types in an in vitro pediatric model. Respir Care. 2015;60:1.  
110. Sweeney L, McCloskey AP, Higgins G, Ramsey JM, Cryan SA, MacLoughlin R. 
Effective nebulization of interferon -gamma using a novel vibrating mesh. Respir 
Res. 2019;20(1):66.  
   
   51 
111. Sagalla R, Smaldone G. Capturing the efficiency of vibrating mesh nebulizers: 
minimizing upper airway deposition. J Aerosol Med Pulm Drug Deliv. 
2014;27(5):[ADDRESS_232894] variability in respi[INVESTIGATOR_196084]. Expert Opin Drug Deliv. 
2018;15(12):[ADDRESS_232895] following aerosol inhalation. J Pharm Sci. 1986;75(5):433- 438. 
114. Ari A, Atalay O, Harwood R, Sheard M, Aljamhan E, Fink J. Influence of nebulizer 
type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult 
lung models during mechanical ventilation. Respir Care. 2010;55(7):845- 851. 
115. Alhamad BR, Fink JB, Harwood RJ, Sheard MM, Ari A. Effect of aerosol devices 
and administration techniques on drug delivery in a simulated spontaneously 
breathing pediatric tracheostomy model. Respir Care. 2015;60(7):1026- 1032.  
116. Mallol J, Rattray S, Walker G , Cook D, Robertson C. Aerosol deposition in infants 
with cystic fibrosis. Pediatr Pulmonol. 1996;21(5):276- 281. 
117. Chua H, Collis G, Newbury A, et al. The influence of age on aerosol deposition in 
children with cystic fibrosis. Eur Respir J. 1994;7(12): 2185 -2191.  
118. Mukhopadhyay S, Staddon G, Eastman C, Palmer M, Davies E, Carswell F. The 
quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir 
Med. 1994;88(3):203- 211. 
119. Touw D, Brimicombe R, Hodson M, Heijerman H, Bakker W. Inhalation of antibiotics 
in cystic fibrosis. Eur Respir J. 1995;8(9):1594 -1604.  
120. Dhand R. How Should Aerosols Be Delivered During Invasive Mechanical 
Ventilation? Respir Care. 2017;62(10):1343- 1367.  
121. Geller D, Rosenfeld M, Waltz D, Wilmott  R, Group ATS. Efficiency of pulmonary 
administration of tobramycin solution for inhalation in cystic fibrosis using an 
improved drug delivery system. Chest. 2003;123(1):[ADDRESS_232896] ident ification of 
nephrotoxin exposure and associated acute kidney injury. Pediatrics. 2013;132(3):e756 -767. 
123. Fisher D. Clinical pharmacology of neuromuscular blocking agents. Am J Health Syst Pharm. 1999;56([ADDRESS_232897] 1):S4- 9. 
 
  
   
   52 
APPENDIX  
 
Appendix A:  List of nephrotoxic medications122 
 
Acyclovir  
Ambisome  
Amikacin  
Captopril  
Carboplatin  
Cefotaxime  
Ceftazidime  
Cefuroxime  
Cidofovir  
Cisplatin  
Colistimethate  
Cyclosporine  
Dapsone  
Enalapril  Foscarnet  
Gadopentetate 
dimeglumine  
Ganciclovir  
Gentamicin  
Ibuprofen  
Ifosfamide  
Iodixanol  
Iohexol  
Iopamidol   
Ioversol  
Ketorolac  
Lisinopril  
Lithium  Mesalamine  
Methotrexate  
Nafcillin  
Pi[INVESTIGATOR_196085]/clavulanic acid  
Tobramycin  
Topi[INVESTIGATOR_196086] 
 
 
  
   
   2 
Appendix B: List of neuromuscular blocking agents123 
 
Altracurium  
 Cisatracurium  
 
Doxacurium  
 Metrocurine  
 
Mivacurium  
 
Pancuronium  
 
Pi[INVESTIGATOR_196087]  
   
   
   3 
Appendix C: Inhaled tobramycin  label  
 
Appendix D: Aerogen ® Solo FDA approval letter  
 
Appendix E: Aerogen ® Solo System Instruction Manual  
 